CELL 2025

11 - 12 November 2025 | London, UK

+Pre-Event Focus Day: 10 November 2025

Connecting Leaders From Every Stage of the Value Chain to Drive Advanced Therapy Development & Novel Biologics Processing

10+ Content Tracks

10+ Hours of meetings

45+ Partners

800+ Attendees

Composed of 3 Groundbreaking Programmes Plus Dedicated Start-Up and Innovation Tracks!

- **Cell Culture & Bioprocessing**
- **Advanced Therapy Development**
- **Cell & Gene Therapy Manufacturing**
- **Start Up Zone & Innovation Tracks**

Meet Your KEYNOTE SPEAKERS

DAY TWO | 09:00

PROFESSOR DAME MOLLY STEVENS

John Black Professor of Bionanoscience, **University of Oxford**

DAY ONE | 09:00

BOBBY GASPAR

Co-Founder & Chief Executive Officer, **Orchard Therapeutics**

DAY ONE | 09:25

CHRISTOF VON KALLE

Director, BIH & Charité Clinical Study Center BIH Chair for Clinical and Translational Sciences Director, **Research Clinic Luxemburg**

+ YOUR EVENT HOST: ERIN HARRIS, CHIEF EDITOR, CELL & GENE

Book Now!

Complimentary Industry, Academic or Investor Guest Passes Available

Register

Sponsor

@NextGenBiomedOG

NextGen Biomed by Oxford Global

WELCOME TO

Cell 2025

Welcome to Cell 2025, Oxford Global's premier event uniting the brightest minds and most transformative innovations in cell culture, bioprocessing, and cell & gene therapy.

Step into the epicentre of advanced therapy development for two immersive days of expertly curated content designed to accelerate the next generation of therapeutic breakthroughs. Featuring a pre-event focus day and with over 800 attendees expected onsite, the event offers unparalleled opportunities to engage with leading scientists, innovators, and decision-makers shaping the future of advanced therapies.

Explore the full industry value chain across three powerhouse programmes:

Cell Culture & Bioprocessing – Advancing stable, scalable, and high-performing cell systems through cutting-edge cell engineering, next-gen bioprocessing technologies, and 3D culture innovations

Advanced Therapy Development – Accelerating the path from discovery to clinical impact with pioneering gene and cell therapy research, robust analytical platforms, and regulatory-ready development strategies

Cell & Gene Therapy Manufacturing – Powering intelligent, end-to-end manufacturing with integrated supply chains and AI-driven production platforms to bring advanced therapies to patients faster

Our dynamic agenda features bold ideas and breakthrough technologies brought to life through visionary keynotes, deep-dive technical talks, start-up spotlights, and curated showcases that spotlight real-world innovation. Expect thought-provoking discussions that bring together industry, academia, and regulatory leaders to address shared challenges and opportunities—from scalability and standardisation to regulatory harmonisation & commercial readiness.

Beyond the main sessions, connect with peers, pioneers, and potential collaborators in our dedicated networking and showcase zones. Whether you're optimising upstream processes, adopting automation, or reimagining manufacturing with AI, Cell 2025 is your gateway to the future of bioprocessing and cell & gene therapies.

Eszter Sutowski Nagy
Senior Production Director, Oxford Global

Unlock The Latest News & Insights

Sign up for our monthly newsletter to keep up with all things NextGen Biomed

Click Here

BROCHURE CONTENTS

Book Now

LinkedIn
@NextGenBiomedOG

WHAT'S NEW

Benefits Of Attending

Take a deep dive into the latest strategies for enabling successful cell line engineering. Improving efficiency and removing bottlenecks in cell line development, screening clones for productivity, predicting & characterising.

Gain invaluable insights into innovations in pre-clinical assay development & 3D cell cultures. Key opinion leaders will be addressing the integration of iPSC models for pre-clinical studies, 2D versus 3D cultures and case studies highlighting pre-clinical successes and failures.

Discuss regulatory considerations for cell & gene therapies. Presentations will address the regulations surrounding the development of platforms for genetically modified B cells and using accelerated regulatory pathways.

Explore the latest advancements in tissue engineering. Presentations will cover stem cells for cartilage repair, innovative biomaterials, and multi-cell type approaches to tissue regeneration.

Benefit from the latest development in supply chain & logistics. Hear about regulatory compliance in transportation, shipping & tracking of new modalities in the clinic & collaborations across the supply chain.

Explore strategies for adopting AI, automation & robotics in the manufacturing workflows. Join presentations & discussion sessions on automated cell therapy manufacturing & sustainability approaches.

DON'T MISS THESE

Interactive Features

14:40 | DAY 1 PANEL DISCUSSION
Navigating The Analytical Lifecycle: Strategic Management For Streamlined CGT Product Development

17:15 | DAY 1 PANEL DISCUSSION
Novel Formats For Cell Line Engineering

08:30 | DAY 2 ROUNDTABLE
Future Bullet Proof CAR-T Manufacturing

12:00 | DAY 2 PANEL DISCUSSION
Experiences In Executing Cell & Gene Therapy Studies With Patient Engagement In Mind

15:05 | DAY 2 PANEL DISCUSSION
Navigating Global Regulatory Challenges In Cell & Gene Therapy

Where Innovation Ignites Opportunity: Welcome to the Start-Up Zone

Discover the future of advanced therapies at Cell 2025's Start-Up Zone—an exciting launchpad for 10+ pioneering start-ups at the forefront of cell culture, bioprocessing, and next-gen therapy development.

Whether you're pitching your breakthrough, demoing cutting-edge tech, or forging game-changing partnerships, this is your moment to shine. From IP strategy and supply chain readiness to investor insights and commercial potential, the Start-Up Zone is where breakthrough ideas gain the visibility, connections, and critical guidance they need to scale.

It's your opportunity to engage with seasoned experts, strategic partners, and forward-thinking investors ready to shape the future of advanced therapies with you.

Book Now

LinkedIn
@NextGenBiomedOG

WHY PARTNER WITH

OXFORD GLOBAL?

At Oxford Global, our mission is to curate personalised experiences that foster community and inspire innovation.

We believe in the power of networking, connection, and knowledge to deliver quality products and services that exceed expectations. Partnering with Oxford Global means having a dedicated team committed to helping you achieve your goals and navigating the industry's ever-changing landscape.

Arrange 1-1 Meetings

Benefit from guaranteed one-to-one face time with your key prospects, with detailed pre-meeting information provided to enable effective and productive conversations.

Speaking Opportunities

Showcase your company's recent work to a relevant and highly engaged audience.

Host Panel & Roundtable Discussions

Feature alongside key opinion leaders to discuss current hot topics and highlight your company's expertise.

Organise Workshops

Demonstrate best practice within the industry in front of your peers with case studies from your clients.

Exhibit your Products & Solutions

Promote your offerings and ensure delegates know where to find you with a prominent brand presence in the exhibition hall.

Digital Marketing & Lead Generation

Accessing the Oxford Global database, amplify your thought leadership and branding messaging through our digital content initiatives.

LEARN MORE

DRIVE INNOVATION & ACCELERATE RESEARCH

Who Is Partnering?

Diamond Sponsor

Sartorius

Platinum Sponsor

ThermoFisher SCIENTIFIC

Gold Sponsors

10x Genomics · Acro Biosystems · Beckman Coulter Life Sciences · Fluidic Sciences · GenScript Scripting Possibilities · Nova Biomedical

Silver Sponsors

Air Products · aseptic technologies · bioMérieux · Biothrust · CellforCure by Sequens · CoJourney · Concept Life Sciences · Kuhner shaker · Minaris Advanced Therapies · nanji[on · PROGEN

Bronze Sponsors

Bio-Rad · BPES · eppendorf · Hamilton · Miltenyi Biotec · Mytos · Novo Nordisk Pharmatech A/S · novo nordisk · PHCbi A Member of PHC Group · sbi Scientific Bioprocessing · Synentec · Waters

Book Now

LinkedIn
@NextGenBiomedOG

WHY PARTNER WITH

OXFORD GLOBAL?

At Oxford Global, our mission is to curate personalised experiences that foster community and inspire innovation.

We believe in the power of networking, connection, and knowledge to deliver quality products and services that exceed expectations. Partnering with Oxford Global means having a dedicated team committed to helping you achieve your goals and navigating the industry's ever-changing landscape.

Arrange 1-1 Meetings

Benefit from guaranteed one-to-one face time with your key prospects, with detailed pre-meeting information provided to enable effective and productive conversations.

Speaking Opportunities

Showcase your company's recent work to a relevant and highly engaged audience.

Host Panel & Roundtable Discussions

Feature alongside key opinion leaders to discuss current hot topics and highlight your company's expertise.

Organise Workshops

Demonstrate best practice within the industry in front of your peers with case studies from your clients.

Exhibit your Products & Solutions

Promote your offerings and ensure delegates know where to find you with a prominent brand presence in the exhibition hall.

Digital Marketing & Lead Generation

Accessing the Oxford Global database, amplify your thought leadership and branding messaging through our digital content initiatives.

LEARN MORE

DRIVE INNOVATION & ACCELERATE RESEARCH

Who Is Partnering?

Network & Programme Sponsors

ABSELION
AZENTA LIFE SCIENCES
Benchling
BIOCAIR
bio-techne
CellVoyant
CYTENA A BICO COMPANY
CYTOMOS.
EnzyScreen
GETINGE
GORE
GYROS PROTEIN Technologies
Haier Biomedical Intelligent Protection of Life Science
iotaSciences
KING'S College LONDON
octapharma
PhoenixBio
PL BioScience WE DELIVER CELL SOLUTIONS
PromoCell
Roche
Roslin CT
SGS

Start-Up Zone

Avigen
baSeq
bright biotech
Cirena
CoED BIOSCIENCES
Green Elephant BIOTECH
iORGANBIO
QUiCKR
radix.partners

Book Now

LinkedIn
@NextGenBiomedOG

SPECIAL EVENT FEATURES

Big Attendance Meets Intimate Connections

An unmissable journey awaits you: from celebrated keynote speakers to roundtables & fireside chats to an exclusive awards dinner honouring excellence in CGT innovation.

Discover the moments that will transform your Cell 2025 experience.

Breaking Barriers, Shaping Futures – 'Women in Life Sciences' Panel Discussion

Join us on Day 2 on the Visionary Voices stage for a powerful and thought-provoking panel celebrating the women transforming the future of cell and gene therapy.

This dynamic session explores what it means to lead with impact—breaking down barriers, championing inclusive work environments, and empowering the next generation of scientific innovators. Hear from pioneering voices as they share personal stories, hard-won insights, and bold visions for a more equitable life sciences industry.

Moderated by Erin Harris, Chief Editor of Cell & Gene.

Meet Your Host – Erin Harris, Chief Editor, Cell & Gene

Guiding the conversation at Cell 2025 is Erin Harris, Chief Editor of Cell & Gene and a leading voice in the advanced therapies space. With a deep understanding of the industry and a passion for amplifying impactful stories, Erin brings sharp insight, thoughtful perspective, and engaging energy to the stage. From panel discussions to fireside chats, she'll be your go-to guide throughout the event—helping you navigate key sessions, spotlight emerging trends, and connect with the people shaping the future of cell and gene therapies.

Fireside Chats on the 'Visionary Voices' Stage

Get up close and personal with industry trailblazers in our Faireside Chats - informal, candid conversations taking place on 11 November. Hear firsthand how leaders are tackling big challenges in implementing novel technologies such as AI/ML in drug discovery workflows, driving innovation, and shaping the future of drug development. Expect real stories, bold ideas, and valuable insights you won't find in a typical presentation.

Cell 2025 After Hours: Networking Drinks on Day 1

Wrap up Day 1 in style with our exclusive networking drinks reception—where the brightest minds in cell culture, bioprocessing & advanced therapy development come together to spark new ideas, forge powerful connections, and unwind in a vibrant atmosphere. Erin Harris, Chief Editor of Cell & Gene, will kick off the evening, setting the stage for a relaxing drinks reception charged with energy, inspiration, and opportunity. Grab a drink, mix, mingle, and let the conversations flow!

Kickstart Day 2 with Purpose – Roundtable Discussions

Don't miss our exclusive cross-programme roundtables—taking place bright and early from 8:30 to 9:00am. Grab a coffee, pick up a pastry, and engage in dynamic, informal discussions led by advanced therapy experts on the most critical challenges and innovations shaping cell and gene therapy development. It's your opportunity to ignite new ideas, explore cutting-edge solutions, and connect with peers before the day's sessions begin.

Navigating Complexity, Accelerating Access – Regulatory Strategy at the Forefront

As regulatory science races to keep pace with the rapid evolution of cell and gene therapies, Cell 2025 offers a vital platform to explore the latest guidance, global frameworks, and strategies for accelerating approval and patient access. Don't miss a series of expert-led presentations and panel discussions that unpack this fast-moving landscape.

EVENT OVERVIEW

Programme Agenda at a Glance

Cell 2025 explores the entire value chain involved in bringing next-generation biomedicines to market. Deep dive into specific tracks, and enjoy cross-programme features bringing our audience together.

	Pre-Event Day 10 November 2025	Day One 11 November 2025	Day Two 12 November 2025
Cross-Programme Features	N/A	Fireside Chat: Patient Advocacy & Patient Engagement Fireside Chat: CGT Development & Manufacturing	Morning Roundtables Panel Discussion: Cell & Gene Therapy Investment In A Challenging Economy: Navigating Risks & Opportunities Panel Discussion: 'Women in Life Sciences' Panel Discussion on the 'Visionary Voices' Stage
Cell Culture & Bioprocessing	Novel Ideas For Cell Line Development	Cell Line Engineering Ensuring Stability, Quality & Clonality	Generation & Validation Of Pre-Clinical Models & Stem Cells
		Upstream Bioprocessing	Downstream Bioprocessing
Advanced Therapy Development	Autologous vs. Allogenic Products	Gene Therapy Discovery & Development	Cell Therapy Discovery & Development
		Cell & Gene Therapy Analytics & Quality Control	Clinical Development & Clinical Trials For Cell & Gene Therapies
Cell & Gene Therapy Manufacturing	Gene Therapy Development	Strategies & Challenges For Gene Therapy Manufacturing	Strategies For Cell Therapy Manufacturing
		Supply Chain, Logistics & Commercialisation	
Start Up Zone + Innovation & Collaboration Programme	N/A	The Start Up Zone programme on Day 1 is designed to support young start-ups working on new technologies, platforms, solutions to showcase their innovative thinking and bring new ideas.	Day 2 also features 10-minute presentations from emerging biotechs and academic spin-offs advancing cell culture development, advanced therapies and manufacturing, with specific focus on IP, funding priorities & challenges, cell & gene therapy investments.

Book Now

AGENDA AT A GLANCE

Cell 2025

Cell Culture & Bioprocessing
Programme Overviews

Be part of a premier gathering of leading scientific minds at our Cell Culture & Bioprocessing Programme, where innovation meets application. Explore the latest advancements in integrating iPSC models into pre-clinical studies, compare the impact of 2D versus 3D cultures, and gain valuable insights from real-world case studies showcasing both breakthroughs and challenges. Dive into cutting-edge strategies for streamlining cell line development, enhancing clone screening for productivity, and improving predictability and characterisation, driving efficiency and eliminating bottlenecks in the bioprocessing pipeline.

VPs, Directors & Senior Managers from leading pharma & biotech companies and research institutions in the following fields and more:

- Cell Line Engineering
- Cell Culture
- Potency Assay
- Bioprocessing
- Cell Models
- ATMP
- Cell Banking
- Cellular Operations
- Automation

Formal and informal meeting opportunities offer delegates the chance to discuss key solutions with leading service providers:

- Cell Culture Media
- Cell Line Development
- Automation
- Bioreactor
- Analytics
- Flow Cytomentry
- Cell Line Engineering
- Continuous Biomanufacturing

Day 1 Track 1: Cell Line Engineering Ensuring Stability, Quality & Clonality

- Improving efficiency and removing bottlenecks in cell line development
- Clone selection strategies and establishing monoclonality
- Screening clones for productivity and titer
- Strategies for single-cell isolation
- Predicting & characterising clones
- Improving the stability of cell lines via optimised transfection
- Gene delivery & editing for cell line development
- Regulatory considerations to develop stable cell lines
- Novel formats

Day 1 Track 2: Upstream Bioprocessing

- High throughput technologies in bioprocessing
- Automation & robotics
- Software & AI
- Improving instrumentation for biopharmaceutical drug production
- Bioreactors & perfusion systems
- Leveraging ADC's to streamline drug production processes
- High containment solutions for ADCs
- Online monitoring techniques
- Online sensors for cell culture
- Scale up
- Manufacturing biopharmaceuticals with microbial systems

Day 2 Track 1: Generation & Validation of Pre-Clinical Models & Stem Cells

- Advances in 3D cultures and their role in translational research
- Integration of iPSC models for pre-clinical studies
- Strategies to progress research with or without animal models
- Case studies highlighting successes and failures
- Real-world examples of assay development and validation
- Insights into gene target validation and optimisation
- Optimising cell culture & media development:
  - » Techniques for enhancing cell culture productivity

Day 2 Track 2: Downstream Bioprocessing

- Data for downstream processing
- PAT tools for predictivity
- Facilitating technology transfer for cell-based products
- Reducing timelines in bioprocessing
- Host cell proteins & removing impurities
- Analytical approaches – AV characterisation, process monitoring & product analysis
- How to deal with large protein quantities generated by upstream bioprocessing
- Viral validation – new considerations & approaches
- Establishment of fast microbiological testing

Book Now

Advanced Therapy Development
Programme Overviews

Advance the future of medicine at our Advanced Therapy Development Programme, where leaders in gene and cell therapy converge. Explore the latest in vector design, gene editing, analytics, AI-driven quality control, clinical trials, and regulatory strategy. From iPSC and stem cell innovations to next-gen immunotherapies and tissue engineering, gain critical insights across discovery, development, and clinical translation. Accelerate your impact in the rapidly evolving world of cell and gene therapy.

VPs, Directors & Senior Managers from leading pharma & biotech companies and research institutions in the following fields and more:

- Cell Therapy
- Gene Therapy
- Stem Cell Therapy
- Commercialisation
- Preclinical Assessments
- Clinical Development
- Regenerative Medicine
- Regulatory Affairs

Formal and informal meeting opportunities offer delegates the chance to discuss key solutions with leading service providers:

- Off-The-Shelf Therapies
- Preclinical Testing
- Clinical Trial
- Safety
- Commercial Readiness
- iPSCs
- In Vivo Models
- Functional Assays
- Viral Vectors

Day 1 Track 3: Gene Therapy Discovery & Development

- Vector engineering: designing and optimising viral and non-viral vectors for efficient therapeutic delivery
- Next-gen strategies: gene editing technologies
- Preclinical validation, assessing safety and efficacy, including off-target effects
- How to design a gene therapy clinical trial
- Nonmonogenetic gene therapies

Day 1 Track 4: Cell & Gene Therapy Analytics & Quality Control

- Raw material management
- Analysing and monitoring processes to ensure product quality
- Starting materials, process control
- Characterising cell-based therapies
- Incorporation of omics, AI/ML to close the gaps in data
- Novel approaches to cell culture process control strategies
- Vector characterisation
- Gene expression analytics
- Formulation development with AI/ML & overcoming stability & characterisation challenges

Day 2 Track 3: Cell Therapy Discovery & Development

- NK, TCR, innate killer cell therapies
- Combination therapies for immunotherapeutic response
- Cell therapies for solid tumours, blood-based cancers & autoimmune diseases
- Part 2 – iPSCs and Stem Cell Therapy Development
- Delivering stem cell therapies from discovery to the clinic
- Stem cell discovery & development: neurodegenerative & cardiovascular diseases, paediatrics
- The role of stem cell-derived disease models in drug discovery
- The use of stem cells in regenerative medicine & tissue engineering
- Derivation, manipulation, and characterisation of iPSCs
- Strategies to control and optimise stem cell bioprocessing

Day 2 Track 4: Clinical Development & Clinical Trials For Cell & Gene Therapies

- Defining a clinical trial strategy for CGT therapies
- From bench to bedside-translational case studies
- Improving CAR-T potency for solid tumours
- Patient engagement in clinical trials and patient-centered clinical trial design
- Real-world evidence and post market surveillance
- CRISPR use within clinical trials
- Individualised therapy considerations in clinical trials
- The roadmap for the first human clinical trial
- Data integrity

Cell & Gene Therapy Manufacturing
Programme Overviews

Discover the forefront of innovation in cell and gene therapy manufacturing at our expertly curated programme. Gain insights into scalable manufacturing strategies, supply chain innovation, AI-driven automation, and the latest in regulatory, quality, and commercialisation approaches. With expert-led sessions on vector production, digitalisation, cryopreservation, and autologous vs. allogeneic platforms, this is your opportunity to tackle the key challenges of bringing CGT therapies from R&D to the clinic and beyond. Be part of the movement shaping the future of scalable, sustainable, and patient-centric advanced therapy manufacturing.

VPs, Directors & Senior Managers from leading pharma & biotech companies and research institutions in the following fields and more:

- Gene Therapy Manufacturing
- Cell Therapy Manufacturing
- Supply Chain
- Process Development
- Viral Vector Manufacturing
- Commercialisation
- CMC
- CMC Development

Formal and informal meeting opportunities offer delegates the chance to discuss key solutions with leading service providers:

- Supply Chain Logistics
- Process Analytical Technology
- GMP Manufacturing
- Process Improvement
- Automation
- Cold Chain
- Commercialisation
- AI & Automation

Day 1 Track 5: Strategies & Challenges for Gene Therapy Manufacturing

- Scale-up challenges and strategies
- Implementing continuous manufacturing processes
- Quality by Design approaches
- Utilising single-use technologies
- Leveraging bioinformatics and digital twin technology
- Scalable platforms for vector production; optimising quality and yield
- Transitioning from R&D to clinical manufacturing: navigating the path to commercialisation
- Lipid nanoparticles & biodistribution
- Sustainable manufacturing, cost effectiveness & scalability integration
- types: MSCs, iPSCs, fibroblasts, NPCs

Day 1 Track 6: Supply Chain, Logistics & Commercialisation

- Regulatory compliance in transportation and storage
- Cold chain management for product integrity
- Optimising transportation routes and inventory management
- Collaboration and partnerships across the supply chain
- Cryopreservation
- How to bring new modalities into the clinics – shipping & tracking
- Strategies for commercialisation of CGT Therapies
- Regulatory & IP considerations
- Navigating competitive market landscapes
- Global market expansion
- Patient-centred product launch
- Off-the-shelf CGT therapies

Day 2 Track 5: Strategies for Cell Therapy Manufacturing

- Autologous vs. allogenic products
- Transitioning to cGMP manufacturing
- Regulatory insights and compliance considerations
- Ensuring sustainable product pipeline
- Analytical techniques: quality control and assurance
- Transitioning from R&D to clinical manufacturing: navigating the path to commercialisation
- Platform concepts – how CAR-Ts can be manufactured & streamlining the pipelines
- Sustainable manufacturing

Book Now

IDEAS THAT INSPIRE. LEADERS WHO DELIVER.

Introducing Our Keynote Speakers

DAY ONE | 09:00

HSC Gene Therapy For Severe Genetic Diseases - From Development, Manufacture To Commercialisation

BOBBY GASPAR, Co-Founder & Chief Executive Officer, Orchard Therapeutics

Orchard therapeutics

Bobby is a **world-renowned scientist and physician** and accomplished strategic and organisational leader with more than **25 years of experience in medicine and biotechnology**. He is one of the principal scientific founders and current chief executive officer of Orchard Therapeutics, a global gene therapy leader recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe.

Bobby has been a **pioneer in gene therapy** and the evolution of hematopoietic stem cell (HSC) gene therapy technology. His unparalleled expertise and deep relationships with key physicians and treatment centres around the world are integral to Orchard's efforts to identify patients with metachromatic leukodystrophy (MLD) and other severe genetic conditions through targeted disease education, early diagnosis and comprehensive newborn screening. **Bobby was named to the inaugural TIME100 Health list** in 2024, recognising him as one of the world's most influential individuals impacting human health.

DAY ONE | 09:25

An All Stakeholder Approach To Cell & Gene Therapy

CHRISTOF VON KALLE, Director, BIH & Charité Clinical Study Center BIH Chair for Clinical and Translational Sciences Director, Research Clinic Luxemburg

LUXEMBOURG INSTITUTE OF HEALTH

Professor Dr. Christof von Kalle is **one of the most influential figures in translational medicine** and gene therapy, widely recognised for his pioneering contributions to cancer research and stem cell biology.

His **groundbreaking work has been honoured with some of the field's most prestigious awards**, including the **American Society of Gene Therapy's Young Investigator Award**, the **Langen Research Award**, the **Eva Luise Köhler Prize for Rare Diseases**, and the **Human Gene Therapy Pioneer Award.**

These accolades not only reflect his scientific excellence but also his lasting impact on shaping the future of precision medicine, driving innovation from bench to bedside.

DAY TWO | 09:00

Smarter, Faster, Healthier: Making The Most Of AI & Bioengineering Breakthroughs

DAME MOLLY STEVENS, John Black Professor of Bionanoscience, University of Oxford

UNIVERSITY OF OXFORD

Professor Dame Molly Stevens DBE FRS FREng FMedSci joined as the John Black Professor of Bionanoscience in April 2023 at the Institute of Biomedical Engineering and the Department of Physiology, Anatomy & Genetics, and Deputy Director of the Kavli Institute for Nanoscience Discovery.

Professor Dame Molly Stevens is an international leader in ground-breaking biosensing technologies, transformative regenerative medicine and advanced therapeutic approaches. She is a serial entrepreneur and has significant expertise and experience in commercialisation of devices, with numerous patents filed and 4 spin-out companies based on her research.

Professor Dame Stevens has won >40 awards, including the **Novo Nordisk Award in 2023**, the **MRS Mid-Career Researcher Award** in 2022, and the **American Chemical Society Award in Colloid Chemistry** in 2020. Professor Dame Stevens is a **Fellow of 8 Professional Bodies**, including the Royal Society (FRS) and Royal Academy of Engineering (FREng), and is also a **Foreign Member of the National Academy of Engineering** and an **International Honorary Member of the American Academy of Arts and Sciences.**

Amongst many leadership roles, Professor Dame Stevens is Director of the UK Regenerative Medicine Hub for Acellular Smart Materials and Deputy Director of the EPSRC-Interdisciplinary Research Collaboration i-sense for biosensing.

ALL PROGRAMMES

Spotlight Speakers

Spotlight Speaker 09:50 | Day 1

JON BEAMAN, Deputy Director Innovative Medicines, MHRA

Presenting on 'Advancements At The MHRA To Support ATMP Development'

This presentation offers a comprehensive overview of the advancements at the MHRA. Attendees will gain insights into the support being offered for ATMP development inlcuding significant investments, technologies and strategies.

Spotlight Speaker 09:50 | Day 1

FRANÇOIS GIANELLI, Chief Regulatory & Quality Officer, TreeFrog Therapeutics

Presenting on 'New Manufacturing Modalities For Cell Therapies And Regulatory Challenges'

This presentation will explore innovative manufacturing modalities for cell therapies, addressing how emerging technologies are reshaping production processes. It will also examine the evolving regulatory landscape, offering strategies to navigate compliance challenges while integrating automation in manufacturing workflows.



Spotlight Speaker 09:25 | Day 2

BEN WEIL, Chief Operating Officer & Chief Manufacturing Officer, INmune Bio

Presenting on 'Autologous & Allogenic Products'

This presentation will delve into the key manufacturing considerations for both autologous and allogeneic cell therapies, comparing their unique challenges and opportunities. It will offer strategic insights into optimising production workflows, scalability, and cost-effectiveness across both approaches.

Spotlight Speaker 09:25 | Day 2

RUTH FARAM, Co-Founder & Chief Scientific Officer, SymphoRNA

Presenting on 'Using RNA To Program In Vivo & Ex Vivo Therapies'

This presentation will highlight cutting-edge advances in using RNA to reprogram cells both in vivo and ex vivo, unlocking new possibilities for precise and efficient cell therapies. It will provide valuable perspectives on how RNA-based approaches are accelerating discovery and development in the cell therapy pipeline.

ALL PROGRAMMES

Spotlight Speakers

Spotlight Speaker | 16:05 | Day 1

TERRI GASKELL, Chief Technology Officer, Rinri Therapeutics

Joining our CGT Development & Manufacturing Fireside Chat

This Fireside Chat will explore innovative development & manufacturing strategies tailored to the complexities of cell and gene therapies, ensuring robust and efficient clinical outcomes.

Spotlight Speaker | 14:40 | Day 2

NITIN PATEL, Vice President of Late-Stage Clinical Development, Legend Biotech

Presenting on 'Cilta-cel: Changing The Treatment Paradigm In Multiple Myeloma'

This presentation will provide an in-depth look at the clinical development programme of Cilta-Cel, offering key insights into trial design, data outcomes, and regulatory progress. Attendees will gain a clearer understanding of how this CAR-T therapy is advancing toward broader clinical adoption and commercial readiness.

Spotlight Speaker | 12:25 | Day 1

LIZ RAMSBURG, Head of Research, Roche Innovation Center Philadelphia

Presenting on 'Developing & Delivering Gene Therapies For Inherited Diseases'

This presentation will showcase the latest scientific and technological advances driving innovation in gene therapy development. It will provide attendees with a forward-looking view of how these breakthroughs are shaping the next generation of gene therapies.

Spotlight Speaker | 16:35 | Day 2

JOE BETTS-LACROIX, Chief Executive Officer, Retro Bioscience

Presenting on 'AI For Rejuvenation & Replacement Therapies'

This presentation will explore the use of AI for rejuvenation and replacement therapies, addressing how emerging technologies are provding new opportunities for vital development. It will also examine autologous iPSC-derived hematopoietic stem cells for immune and blood system rejuvenation as well as translating rejuvenation biology into next-generation cell therapies.

ALL PROGRAMMES

Confirmed Speakers

BOBBY GASPAR,
Co-Founder & Chief Executive Officer, Orchard Therapeutics

DAME MOLLY STEVENS,
John Black Professor of Bionanoscience, University of Oxford

CHRISTOF VON KALLE,
Director, BIH & Charite Clinical Study Center
BIH Chair for Clinical and Translational Sciences
Director, Research Clinic Luxemburg

JOANNA BREWER,
Former Chief Scientific Officer, Adaptimmune

BO WIINBERG,
Chief Development Officer, Novo Nordisk Foundation Cellerator

FRANÇOIS GIANELLI,
Chief Regulatory & Quality Officer, TreeFrog Therapeutics

JOE BETTS-LACROIX,
Chief Executive Officer, Retro Biosciences

ERMIR KALAJ,
Chief Executive Officer, Cellula Therapeutics

BEN WEIL,
Chief Operating Officer & Chief Manufacturing Officer, INmune Bio

RUTH FARAM,
Co-Founder & Chief Scientific Officer, SymphoRNA

KRISTIAN TRYGGVASON,
Co-Founder & Chief Executive Officer, Alder Therapeutics

IBON GARITAONANDIA,
Chief Scientific Officer, CellProthera

KATY TROST,
Chief Executive Officer Coach & Advisor/Founder, Pera CEO Network

PANTELI THEOCHAROUS,
Chairman of the Board of Directors, TMOIF & Chief Executive Officer, VectorGen

ROELOF RONGEN,
Co-Founder & Board Director, AeirBio

DEBESH MANDAL,
Co-Founder & Chief Executive Officer, Nanograb

TERRI GASKELL,
Chief Technology Officer, Rinri Therapeutics

PETER ANDERSEN,
Chief Research & Development Officer, TreeFrog Therapeutics

SANJEEV LUTHER,
President & Chief Executive Officer, Ernexa Therapeutics

LINDSAY DAVIES,
Chief Scientific Officer, NextCell Pharma

JOSHUA BAGLEY,
Chief Scientific Officer, a:head Bio

JAS UPPAL,
Senior Vice President Head of Regulatory, BlueRock Therapeutics

RACHEL HAINES,
Vice President, Clinical Development & Operations, Rinri Therapeutics

NITIN PATEL,
Vice President of Late-Stage Clinical Development, Legend Biotech

LIZ RAMSBURG,
Head of Research, Roche Innovation Center Philadelphia

THORSTEN GORBA,
Vice President Process & Analytical Development, Aspen Neuroscience

JON BEAMAN,
Deputy Director Innovative Medicines, MHRA

NICOLE LUND,
Senior Quality Control Director, Bluerock Therapeutics

KERRY SIEGER,
Vice President of Global Quality Operations, Immatics

MATT STONE,
Director of Supply Chain, REGENXBIO

SARAH SNYKERS,
Senior Director of Operations, Legend Biotech

CHIARA RECCHI,
Director, Research & Discovery, Orchard Therapeutics

RHIANNON DAVID,
Senior Director, Head of Advanced Cell Models, Safety Sciences, AstraZeneca

CHIEN-CHUNG CHEN,
Senior Director, Analytical Development, Cabaletta Bio

MARINA TARUNINA,
Research Director, Plasticell

CORNEL CHIRIAC,
Investment Director, M&G Crossover Fund

PAULINE LESTRINGANT,
Director Regulatory Science, Voisin Consulting Life Sciences

ARINDAM MITRA,
Director of CMC, Leucid Bio

MONICA RAIMO,
Director of Product & Process Development, Glycostem

THIJS GERRITZEN,
Director CMC Development, Amarna Therapeutics

DIANA HERNANDEZ,
Director of Immune and Advanced Therapies, Anthony Nolan

ALL PROGRAMMES

Confirmed Speakers

LILIAN HOOK,
Director Cell, Apheresis & Gene Therapies, NHS Blood and Transplant

RICHARD FORSEY,
Project Specialist, NHS Blood and Transplant

LUCY WILLIAMS,
Partner, European & UK Patent Attorney, J A Kemp

KEITH WONG,
Associate Director of Process Development, Autolus

SARA RAMOS,
Senior Investigator-Cell Sciences, IG Innovate

CLAIRE IRVINE,
European & UK Patent Attorney Of Counsel, Beck Greener

CLAIRE KERRIDGE,
Head of Gene Therapy, MHRA

SABINA LANCASTER,
Technical Programme Head, Legend Bio

CRISTINA PEIXOTO,
Head of Downstream Process Development Lab & Coordinator Of Bioproduction Unit, iBET

DARIA MARSH,
Head of Bioprocessing, Cell and Gene Therapy Catapult

KIRAN MOYO,
National Senior Manager, NHS England

ULRICH RÜMENAPP,
Senior Biotech Program Lead, Bayer

SUJITH SEBASTIAN,
Viral Vector Hub Manager, NHS Blood & Transplant

SARAH MCALEER,
Pharmacy Lead - Innovative Treatments, NHS

KATERINA RIGAKI,
Upstream Manager, PD Vector, Autolus

SVEN KILI,
Partner, Saisei Ventures

BART ROYENS,
Senior Scientist, MSAT USP, Sanofi

EDWIGE GROS,
Senior Principal Scientist, Amgen

TATYANA PONOMARYOV,
Principal Scientist, Plasticell

JULIEN FLEURENCE,
Discovery Safety Specialist, AstraZeneca

GEMMA EVERITT,
Senior Research Scientist, UK Cell Culture & Banking, AstraZeneca

MARIA BARREIRA GONZALEZ,
Programme Head of Gene Modification, Cell & Gene Therapy Catapult

MARCIA MATA,
Programme Head of Automation, Cell & Gene Therapy Catapult

JULIE BEAUDET,
Chemistry, Manufacturing, & Control Senior Staff Scientist, Regeneron

VINCENZO DI CERBO,
Programme Head of Digital Innovation, Cell and Gene Therapy Catapult

MITCHELL BRAAM,
Scientist, Cell and Gene Therapy Catapult

TAMARA STRAUB,
Senior Scientist, Boehringer Ingelheim

AYCA CETINKAYA,
Senior Scientist, AstraZeneca

LINN MARIE KREINS,
Scientist, Bluu Seafood

DAVID ROIG-CARLES,
Principal Scientist Process Development, Apatimmune

JAMES MATTHEWS,
Senior Scientist, PureSpring Therapeutics

TAISIIA MUKII,
Founding Ambassador, Women In STEM Network

GIACOMO DOMENICI,
Research Scientist, iBET

LEILA ABBAS,
Preclinical Lead, Rinri Therapeutics

VASILIKI KALODIMOU,
Professor, European University-Cyprus – Frankfurt Branch

TIFFANY RAU,
Professor Biochemistry & Cell Biology, University College Cork

JESSICA WHELAN,
Lecturer, University College Dublin

ALINE MILLER,
Professor, University of Manchester

MARYNA PANAMAROVA,
3D Cellular Modelling Specialist, Cellular Operations, Wellcome Sanger Institute

FRANK STAAL,
Professor of Stem Cell Biology, Leiden University Medical Center

ALL PROGRAMMES

Confirmed Speakers

ROBERT ZWEIGERDT,
Professor & Principal Investigator, Hannover Medical School

KENNY DALGARNO,
Professor, Newcastle University

DUYGU DIKICIOGLU,
Associate Professor, University College London

HUAIYU YANG,
Senior Lecturer, Loughborough University

CLARE SELDEN,
Professor of Experimental Hepatology, University College London

MARTIN BORNHÄUSER,
Professor, King's College London

MALI ESKANDARPOUR,
Senior Research Fellow, University College London

Scientific Partners:

SAXOCELL

cell & gene

DON'T MISS THIS

Exclusive Investor Insights

15:05 | DAY 1 PANEL DISCUSSION

Cell & Gene Therapy Investment In A Challenging Economy: Navigating Risks & Opportunities

Where is the smart money going in Cell & Gene Therapy? Join industry leaders and investors from PeraCEOs, M&G Crossover Fund, Beck Greener and Saisei Ventures as they decode the CGT investment landscape—spotting trends, avoiding pitfalls, and revealing the next big hotspots. Discover how aligning your business and IP strategy can unlock greater value, learn how to overcome funding hurdles in a crowded market, and explore the smartest routes to secure investment from early innovation through to late-stage breakthroughs. If you're looking to power CGT progress in tough economic times, this is the session you can't afford to miss.

Book Now

LinkedIn
@NextGenBiomedOG

Pre-Event Day | 10 November 2025

12:30 **Registration**

CELL CULTURE & BIOPROCESSING

NOVEL IDEAS FOR CELL LINE DEVELOPMENT
CONFERENCE ROOM 6: BOURG

Track Chair:
TIFFANY RAU, Professor Biochemistry & Cell Biology, **University College Cork**

13:30 **Emerging Technologies For High-Throughput Cell Line Screening & Selection**

This presentation will explore cutting-edge technologies and automation strategies that are transforming cell line development (CLD) workflows, particularly in high-throughput screening and clone selection.

EDWIGE GROS, Senior Principal Scientist,
Amgen

Q&A session & transition time between conference rooms

13:55 **Variant Interpretation In HEK293: Leveraging Genomic Heterogeneity For Context-Aware Cell Line Development**

HEK293 cell line is foundational in both cell and gene therapy manufacturing and across biomedical research. Yet, the genomic structures of HEK293 and its derivative HEK293T remain poorly defined, with assumptions frequently based on single laboratory data. Adenoviral transformation and long-term propagation have driven extensive structural variation, ploidy alterations, and chromosomal instability across HEK293 cells. This talk will discuss the heterogeneity of HEK293 whole genome sequencing data generated across multiple laboratories, platforms, and geographic regions for capturing the true complexity of unstable genomes to support cell line development.

DUYGU DIKICIOGLU, Associate Professor,
University College London

Q&A session & transition time between conference rooms

INTERACTIVE

14:20 ***Roundtable Discussion 1:*** **Leveraging Automation And AI For Optimising Growth, Productivity, And Stability**

- Using AI and automation to boost productivity and process stability
- Data-driven strategies to optimise cell growth and yield

Moderator:
EDWIGE GROS, Senior Principal Scientist,
Amgen

Roundtable Discussion 2: **Multi-Omics Data For Effective Cell Line Design & Engineering Of Cell based Therapies & Biologics**

- Role and utility of different omics as a driver for cell design and engineering
- Challenges associated with the production and analysis of omics data
- Handling and managing large data sets in a practical setting
- Readiness and resource requirements to deliver this agenda

Moderator:
DUYGU DIKICIOGLU, Associate Professor,
University College London

CELL & GENE THERAPY MANUFACTURING

AUTOLOGOUS VS. ALLOGENIC PRODUCTS
CONFERENCE ROOM 3: COGNAC

Track Chair:
DAVID ROIG-CARLES, Principal Scientist Process Development, **Adaptimmune**

13:30 **From Weeks To Days - Developing A Rapid Manufacturing Process For TCR-Engineered T Cells**

- Traditional vs rapid manufacture of autologous T cells
- Selection of T-cell activation reagent for rapid T-cell manufacture
- Functional evaluation of T cells manufactured in 2 or 3 days
- Challenges of rapidly manufactured T cells to treat solid tumours

DAVID ROIG-CARLES, Principal Scientist Process Development,
Adaptimmune

Q&A session & transition time between conference rooms

INTERACTIVE

13:55 ***Panel Discussion:*** **Autologous vs. Allogeneic Manufacturing: Navigating The Trade-Offs Between Personalisation And Scalability**

- Manufacturing complexity & cost
- Regulatory & quality considerations
- Technological innovation & future outlook

Moderator:
THORSTEN GORBA, Vice President Process & Analytical Development, **Aspen Neuroscience**
Panellist:
KEITH WONG, Associate Director of Process Development, **Autolus**
CHIEN-CHUNG CHEN, Senior Director, Analytical Development, **Cabaletta Bio**

Pre-Event Day | 10 November 2025

ADVANCED THERAPY DEVELOPMENT
GENE THERAPY DEVELOPMENT
CONFERENCE ROOM 6: BOURG

CELL & GENE THERAPY MANUFACTURING
AUTOLOGOUS VS. ALLOGENIC PRODUCTS
CONFERENCE ROOM 3: COGNAC

14:45 - 15:00 **REFRESHMENTS**

Ex-Vivo HSC Gene Therapy Beyond Neurometabolic Disorders, What's Next?

15:00 - 15:25

Hematopoietic stem cells have the potential to differentiate in all types of immune cells, including gut macrophages and brain microglia cells, thus broadening the possibility of treating other diseases such as Crohn's and Frontotemporal Dementia.

CHIARA RECCHI, Director, Research & Discovery,
Orchard Therapeutics

Q&A session & transition time between conference rooms

INTERACTIVE

Panel Discussion: Innovating At The Front End: Bridging Academia And Industry To Overcome Bottlenecks In Gene Therapy Discovery And Early Development

- Target identification & validation
- Vector engineering & payload design
- Developability & translational readiness

15:25 - 15:50

Moderator:

LEILA ABBAS, Preclinical Lead, **Rinri Therapeutics**

Panellists:

CHIARA RECCHI, Director, Research & Discovery, **Orchard Therapeutics**
TIFFANY RAU, Professor Biochemistry & Cell Biology, **University College Cork**

15:50 - 17:00 *Attendees Are Welcome To Join Co-Located Sessions*

INTERACTIVE

Sponsored Workshop:

Fast And Robust Plasmid DNA Purification Process To Support Advanced Therapy Development

Plasmid DNA is a key raw material in advanced therapies, particularly for viral gene therapies and mRNA-based therapies. With a rapid increase in clinical trials approvals of new advanced therapies, the demand for pDNA is rising significantly, necessitating efficient, reliable, and cost-effective production processes. Plasmid DNA production faces a challenge in preserving the integrity of supercoiled isoform and achieving high recovery rates from alkaline lysis through to final filtration. We will present a purification process that achieves >98% supercoiled isoform and >64 % overall DSP process recovery and will cover continuous alkaline lysis, clarification and chromatography. Selective hydrophobic interaction chromatography (SHIC) approach to remove residual impurities and enrich supercoiled pDNA will be presented. A key feature of process development approach is the use of PATfix® pDNA analytical platform which enables rapid feedback loop used to control each step of the process.

KLEMEN BOŽIČ**,** Scientist, Process Development mRNA/pDNA,
Sartorius

Advanced Analytics Unlocks Hidden Opportunities To Increase Yield Of mRNA Manufacturing

mRNA is produced through a cell-free in vitro transcription (IVT) process, where RNA polymerase catalyses the formation of mRNA guided by a DNA template. This production can scale from micrograms to multi-grams, with rapid at-line monitoring of nucleoside triphosphates (NTPs) consumption and mRNA production. This allows for quick adjustments to IVT reaction parameters. IVT optimisation is a multi-factorial problem, ideally suited to design-of-experiment approach for optimisation and identification of design space. A data-driven model of process yield (in g/L), including impact of nucleoside triphosphate (NTP) concentration and Mg:NTP ratio on reaction yield can be derived to optimise reaction cost drivers (e.g. RNA polymerase and DNA template), while minimising dsRNA formation, a critical quality attribute in mRNA products. The yield of the IVT reaction can reach 25 g/L in batch. A high-throughput purification train optimisation is performed by coupling multiparallel (96 well) and spin-based purification devices at ug-scale with Design-of-Experiment methodology. mRNA purification is achieved with affinity chromatography selective for polyadenylated mRNA (Oligo dT) coupled with reverse-phase chromatography used to remove IVT components (NTPs, DNA, T7), and IVT by-products, in particular dsRNA, a major immunogenic impurity which activates dsRNA-dependent enzymes and leads to inhibition of protein synthesis. Elimination of dsRNA improves translation and minimises the activation of innate immune response. In the advent of personalised, mRNA-based therapies, such as neoantigen mRNA vaccines, which require multiple milligram administrations, minimisation of innate immune response may be critical to clinical success of mRNA therapeutics.

KLEMEN BOŽIČ**,** Scientist, Process Development mRNA/pDNA ,
Sartorius

Chromatography Purification Combined With Innovative Analytics Of LNP-based Biopharmaceuticals

Innovative solutions with CIM chromatography to improve LNP drug product integrity, activity, recovery rates, and characterisation.

TJAŠA LEBAN, Associate Scientist,
Sartorius

SARTORIUS

17:00 **END OF PRE-EVENT DAY**

Book Now

Day One | 11 November 2025
Welcome & Keynote Address
Conference Room: Morangis - Visionary Voices Stage

07:30 **Registration**

08:45 **Oxford Global's Welcome Address By Eszter Sutowski Nagy, Senior Production Director, Oxford Global**

08:55 **Event Moderator's Welcome By Erin Harris, Chief Editor, Cell & Gene**

09:00 ***OPENING KEYNOTE ADDRESS & Q&A SESSION:*** **HSC Gene Therapy For Severe Genetic Diseases - From Development, Manufacture To Commercialisation**

- Overcoming development and regulatory challenges for specific gene therapies
- Establishing manufacturing and supply chain models for ex vivo gene therapies
- Building market access and reimbursement models for once only potentially curative gene therapies

BOBBY GASPAR, Co-Founder & Chief Executive Officer,
Orchard Therapeutics

09:25 ***KEYNOTE ADDRESS:*** **An All Stakeholder Approach To Cell & Gene Therapy**

The presentation outlines a comprehensive, multi-stakeholder approach to advancing Cell and Gene Therapies (GCT) in Europe. It highlights the fragmented landscape of national strategies and emphasizes the need for an integrated European framework that bridges academia, industry, policymakers, and patient organizations. Drawing on examples such as Germany's National GCT Strategy, the talk illustrates how collaboration, shared infrastructure, and coordinated education and investment programs can accelerate innovation and ensure equitable access to transformative therapies across Europe.

- Fragmented national GCT strategies call for a unified European framework and stronger cross-border collaboration
- Germany's National GCT Strategy serves as a model for multi-stakeholder cooperation across science, industry, and policy
- Vision: a European ecosystem linking education, investment, and data infrastructure to enable sustainable GCT development

CHRISTOF VON KALLE, Director, BIH & Charité Clinical Study Center BIH Chair for Clinical and Translational Sciences Director,
Research Clinic Luxemburg

CELL CULTURE & BIOPROCESSING	START UP ZONE	ADVANCED THERAPY DEVELOPMENT		CELL & GENE THERAPY MANUFACTURING	
TRACK 1: CELL LINE ENGINEERING ENSURING STABILITY, QUALITY & CLONALITY CONFERENCE ROOM 1: MORANGIS	TRACK 2: START UP ZONE CONFERENCE ROOM 2: BOURGOGNE	TRACK 3: GENE THERAPY DISCOVERY & DEVELOPMENT CONFERENCE ROOM 3: COGNAC	TRACK 4: CELL & GENE THERAPY ANALYTICS & QUALITY CONTROL CONFERENCE ROOM 4: MUSCADET	TRACK 5: STRATEGIES & CHALLENGES FOR GENE THERAPY MANUFACTURING CONFERENCE ROOM 5: ALSACE	TRACK 6: SUPPLY CHAIN, LOGISTICS & COMMERCIALISATION CONFERENCE ROOM 6: BOURG
Morning Track Chair: MALI ESKANDARPOUR, Senior Research Fellow, **University College London**	**Morning Track Chair:** ROELOF RONGEN, Co-Founder & Board Director, **AeirBio**	**Morning Track Chair:** LEILA ABBAS, Preclinical Lead, **Rinri Therapeutics**	**Morning Track Chair:** NICOLE LUND, Senior Quality Control Director, **Bluerock Therapeutics**	**Morning Track Chair:** DAVID ROIG-CARLES, Principal Scientist Process Development, **Adaptimmune**	**Morning Track Chair:** STEPHEN SULLIVAN, Director, **Lindville Bio**

Day One | 11 November 2025

CELL CULTURE & BIOPROCESSING

TRACK 1: CELL LINE ENGINEERING ENSURING STABILITY, QUALITY & CLONALITY

CONFERENCE ROOM 1: MORANGIS

Programme Keynote Address:

Integration Of Advanced Cell Models Into Preclinical Safety Assessment: Successes And Challenges

- In Clinical Pharmacology and Safety Sciences at AstraZeneca, we are developing and implementing advanced human cell models representing various organs for safety assessments, each with their specific context of use
- This presentation will showcase examples, illustrating how data from these systems are being leveraged to enhance the human relevance of pre-clinical safety evaluations
- This presentation will also provide an overview to the remaining challenges to adoption and advancements helping to overcome these to facilitate broader adoption in the industry

RHIANNON DAVID, Senior Director, Head of Advanced Cell Models, Safety Sciences, **AstraZeneca**

09:50

Q&A session & transition time between conference rooms

START UP ZONE

TRACK 2: START UP ZONE

CONFERENCE ROOM 2: BOURGOGNE

Start Up Pitch 1:

Green To Scale: Plant-Based Polymer For Efficient Adherent Cell Manufacturing From Small To Large Scale

CellScrew® is a single-use rotating flask made from renewable PLA for scalable adherent cell expansion. The talk covers design principles and process data demonstrating efficient HEK293 growth and compatibility with automated, closed GMP systems. Key topics include scalability, process integration, and sustainability in modern Cell and Gene Therapy manufacturing.

DUNCAN BORTHWICK, Director of Jumbo Growth, **Green Elephant Biotech**

Start Up Pitch 2:

Unlocking The Goldmine Of Public Transcriptomic Data To Optimise Labs From Experiment To Publication Through AI

The GEO database holds over 4.000 publicly available datasets. Much of this data could prove invaluable to labs all over the world designing their own in-house transcriptomics experiments. But the data has remained largely inaccessible until now. The recent developments in the AI space have allowed for the creation of intuitive software platforms, that lets non-bioinformaticians analyse complex biological data using natural language. During this presentation, we will show just how easy it has become to access and investigate the goldmine of freely available data, and how this can empower labs to design better and more novel experiments

MIKKEL REINCKE FUGLSANG, Chief Executive Officer, **baSeq**

ADVANCED THERAPY DEVELOPMENT

TRACK 3: GENE THERAPY DISCOVERY & DEVELOPMENT

CONFERENCE ROOM 3: COGNAC

Programme Keynote Address:

Closing The Gap: Accelerating Stem Cell Therapies From Discovery To Clinical Impact

Explores how we can accelerate stem cell therapies from research to clinical reality. Highlights innovation, collaboration, and solutions to scientific, technical, and regulatory challenges, aiming to close the gap between discovery and transformative treatments through strategic partnerships, infrastructure, and translational expertise.

BO WIINBERG, Chief Development Officer, **Novo Nordisk Foundation Cellerator**

TRACK 4: CELL & GENE THERAPY ANALYTICS & QUALITY CONTROL

CONFERENCE ROOM 4: MUSCADET

Programme Keynote Address:

Advancements At The MHRA To Support ATMP Development

- MHRA licensing resources, processes and performance to support ATMPs
- New and draft guidance
- Rare diseases initiative

JON BEAMAN, Deputy Director Innovative Medicines, **MHRA**

CELL & GENE THERAPY MANUFACTURING

TRACK 5: STRATEGIES & CHALLENGES FOR GENE THERAPY MANUFACTURING

CONFERENCE ROOM 5: ALSACE

Programme Keynote Address:

Integrating Development, Manufacturing, & Regulatory Considerations Into ATMPs

- Best Practices for building a robust technical and regulatory strategy from development to commercialisation
- Examples of implementation of new technologies into ATMPs – the Good and the Bad.
- European Regulations and US Regulations for ATMPs

TIFFANY RAU, Professor Biochemistry & Cell Biology, **University College Cork**

TRACK 6: SUPPLY CHAIN, LOGISTICS & COMMERCIALISATION

CONFERENCE ROOM 6: BOURG

Programme Keynote Address:

New Manufacturing Modalities For Cell Therapies And Regulatory Challenges

This presentation will explore innovative manufacturing modalities for cell therapies, addressing how emerging technologies are reshaping production processes. Using TreeFrog case study on encapsulated iPSCs, it will examine new cell therapy modalities in the currently evolving regulatory landscape, offering strategies to navigate compliance challenges while integrating innovative equipment in manufacturing workflows.

FRANÇOIS GIANELLI, Chief Regulatory & Quality Officer, **TreeFrog Therapeutics**

Day One | 11 November 2025

	CELL CULTURE & BIOPROCESSING	START UP ZONE	ADVANCED THERAPY DEVELOPMENT		CELL & GENE THERAPY MANUFACTURING	
	TRACK 1: CELL LINE ENGINEERING ENSURING STABILITY, QUALITY & CLONALITY CONFERENCE ROOM 1: MORANGIS	TRACK 2: START UP ZONE CONFERENCE ROOM 2: BOURGOGNE	TRACK 3: GENE THERAPY DISCOVERY & DEVELOPMENT CONFERENCE ROOM 3: COGNAC	TRACK 4: CELL & GENE THERAPY ANALYTICS & QUALITY CONTROL CONFERENCE ROOM 4: MUSCADET	TRACK 5: STRATEGIES & CHALLENGES FOR GENE THERAPY MANUFACTURING CONFERENCE ROOM 5: ALSACE	TRACK 6: SUPPLY CHAIN, LOGISTICS & COMMERCIALISATION CONFERENCE ROOM 6: BOURG
10:15	**A Novel Engineered CHO Host Cell Line For High-Titer Production Of Biopharmaceuticals** This presentation explores Sartorius 4Cell® CHO CLD platform, highlighting new engineered host cell line with enhanced productivity and successful production of IgGs, bispecific, and Fc-fusion proteins for robust, scalable biotherapeutic manufacturing. SARTORIUS DR. JIMIT SHAH, Scientist, **Sartorius**	*Start Up Pitch 1:* **Innovative Strategies For Cell Therapy Development & Manufacture** • The Problem: Manufacturing cell therapies is complex, expensive and the cells produced have low potency and high toxicity • Our Solution: Our simple, easy-to-use platform selects the fittest T-cells and gives them tumour-homing capabilities • The Opportunity: Thousands of new cell therapies, especially for solid cancers, need disruptive manufacturing platforms and tumour targeting solutions to improve patient access and outcomes DAVID COE, Chief Executive Officer, **CoED Biosciences** *Start Up Pitch 2:* **From Millions Of Cells To Your Next Immunotherapy Lead** Cell-based immunotherapies hold curative potential but face an 83% failure rate due to poor in-vitro predictability. Avigen, a preclinical CRO, bridges the translational "Death Valley" with its platform by assessing cellular avidity, the interaction strength between immune and cancer cells, enabling faster, more predictive discovery and validation of next-generation cell therapies to turn millions of cells into tomorrow's cures. TOBIAS GAMPER, Co-Founder & Chief Executive Officer, **Avigen**	**Engineering Potent In-Vivo Immune Cell Therapeutics** Despite remarkable success in haematological malignancies, conventional CAR T-cell therapies face major limitations: complex ex vivo manufacturing, variable product quality, delayed availability, and potentially significant toxicity from prolonged immune activation. These constraints restrict their broader use, particularly in autoimmune diseases. We describe a next-generation in vivo CAR T platform that delivers potent CAR constructs directly to T cells in-vivo without the need for lymphodepletion or cell processing, allowing precise control over activity and safety. GenScript Scripting Possibilities SHIMOBI ONUOHA, Chief Technology Officer, **Chimeris**	**"One To Bind Them All"- A Multifunctional Detection Tool For Novel AAV Capsids** The development of AAV-based gene therapies relies on diverse serotypes with distinct tropisms. The field is moving towards engineered capsids for improved efficiency and reduced immunogenicity. As novel capsids emerge, available antibodies and analytical tools often prove insufficient. We developed a recombinant anti-pan AAV antibody with strong binding to multiple serotypes, including novel variants. We present its comprehensive characterization, showing broad cross-reactivity, high sensitivity, and neutralisation. Additionally, we provide proof of concept for its applicability in innovative immunoassays, supporting reliable analysis of evolving AAV platforms. PROGEN MARTIN MÄRZ, Senior Product Manager, **PROGEN**	**From Bench To Market, Walk Together With Skan** Scalability, Manufacturing Cost and Capability and GMP compliance are fundamental key to bring products onto commercial production to global market. One Skan C&G team will introduce our capability for cGMP world. aSEPTIC TECHNOLOGIES KOJI USHIODA, Global Lead, One SKAN C&G Team, **Aseptic Technologies**	*Attendees are welcome to join co-located sessions*

Q&A session & transition time between conference rooms

Day One | 11 November 2025

	CELL CULTURE & BIOPROCESSING	START UP ZONE	ADVANCED THERAPY DEVELOPMENT		CELL & GENE THERAPY MANUFACTURING	
	TRACK 1: CELL LINE ENGINEERING ENSURING STABILITY, QUALITY & CLONALITY CONFERENCE ROOM 1: MORANGIS	TRACK 2: START UP ZONE CONFERENCE ROOM 2: BOURGOGNE	TRACK 3: GENE THERAPY DISCOVERY & DEVELOPMENT CONFERENCE ROOM 3: COGNAC	TRACK 4: CELL & GENE THERAPY ANALYTICS & QUALITY CONTROL CONFERENCE ROOM 4: MUSCADET	TRACK 5: STRATEGIES & CHALLENGES FOR GENE THERAPY MANUFACTURING CONFERENCE ROOM 5: ALSACE	TRACK 6: SUPPLY CHAIN, LOGISTICS & COMMERCIALISATION CONFERENCE ROOM 6: BOURG
10:40	**How Digital Twin Modelling Accelerates Scale-Up And Technical Transfer For Upstream Processes** • Digital twin modelling is a simulation of active cell culture operations based on process understanding, first principles and historical and real time data • Gain insight which data is needed to build a reliable digital twin model for cell culture processes • Understand how the tool can be used to predict impact of changing process parameters on process performance and how sparger selection and gassing control strategies can be defined during technical transfer and scale up • Hear how Sanofi decreases cost and time during technical transfer by minimising the number of technical at scale runs in the presented case studies BART ROYENS, Senior Scientist, **MSAT USP, Sanofi**	*Start Up Pitch 1:* **Operational Playbook For Cell & Gene Therapy Operations** • Orchestrate the HCP–collection–CDMO value triangle for seamless patient-specific supply • Build cross-functional tech ops teams with QA/QC integration for compliance and risk prevention • Master demand planning and patient pipeline forecasting to align capacity with clinical reality • Execute global tech transfers and scale-up strategies with regulatory confidence • Optimise COGS and commercial viability through data-driven economics CRISTIAN CIRCIUMARU, Founder & Managing Director, **Radix Partners** *Start Up Pitch 2* **How Your RNA Is Made Matters** DOUG DELLINGER, Chief Executive Officer, **Cirena**	**Gene Therapies For The Brain; When, How And What Next** • Direct brain injection safe and effective • Highly prevalent diseases may require non-invasive delivery • Brain-penetrant capsids and focused ultrasound assisted delivery may enable whole brain targeting LIZ RAMSBURG, Head of Research, **Roche Innovation Center Philadelphia**	**Starting With The End In Mind: Defining A Sound Analytical Strategy For Cell Therapy Products** • Translating best practices into phase-appropriate analytical strategies, particularly with a view to commercialisation • Understand QbD principles, control strategies for SISPQ and fit-for-purpose analytical method implementation • Address practical approaches to balancing the "unknowns", while driving analytical rigour and increasing levels of compliance NICOLE LUND, Senior Quality Control Director, **Bluerock Therapeutics**	**Innovation Hubs For Gene Therapies In The UK: NHSBT's Viral Vector Platforms For Gene Therapy Translations** • Innovation Hubs for Gene Therapies – advancing UK academic gene therapy research into clinical applications • NHSBT expertise – established GMP manufacturer of plasmids and viral vectors • Comprehensive early-stage support – regulatory guidance and cost-effective GMP-grade materials for gene therapy translation SUJITH SEBASTIAN, Viral Vector Hub Manager, **NHS Blood & Transplant**	**Stem Cell Based Therapy For Post-Acute Myocardial Infarction** • Presentation of Phase 2 clinical results • Development of manufacturing platform • QC assays for release of clinical batches IBON GARITAONANDIA, Chief Scientific Officer, **CellProthera**
11:05 - 12:25	MORNING BREAK & REFRESHMENTS					
	1-2-1 Meetings x4			Poster Displays		

Day One | 11 November 2025

	CELL CULTURE & BIOPROCESSING	START UP ZONE	ADVANCED THERAPY DEVELOPMENT		CELL & GENE THERAPY MANUFACTURING	
	TRACK 1: CELL LINE ENGINEERING ENSURING STABILITY, QUALITY & CLONALITY CONFERENCE ROOM 1: MORANGIS	TRACK 2: START UP ZONE CONFERENCE ROOM 2: BOURGOGNE	TRACK 3: GENE THERAPY DISCOVERY & DEVELOPMENT CONFERENCE ROOM 3: COGNAC	TRACK 4: CELL & GENE THERAPY ANALYTICS & QUALITY CONTROL CONFERENCE ROOM 4: MUSCADET	TRACK 5: STRATEGIES & CHALLENGES FOR GENE THERAPY MANUFACTURING CONFERENCE ROOM 5: ALSACE	TRACK 6: SUPPLY CHAIN, LOGISTICS & COMMERCIALISATION CONFERENCE ROOM 6: BOURG
12:25	**Improving Adeno-Associated Vector (AAV) Production In HEK293 Cells Through Integrative Multiomics And Engineering Biology** This presentation highlights our advances in improving AAV biomanufacturing by: • Uncovering the complexity of HEK293 biology during AAV production • Integrating multiomics data with tailored bioinformatics to reveal novel pathways • Developing engineering biology strategies to enhance productivity and product quality VINCENZO DI CERBO, Programme Head of Digital Innovation, **Cell and Gene Therapy Catapult**	*Start Up Pitch 1:* **Chloroplast Biomanufacturing: Unlocking Scalable And Affordable Growth Factors For The Future Of Cell Innovation** • Growth factors are essential for cell and gene therapy, tissue engineering, and cultivated meat but remain a major cost bottleneck • Current microbial and mammalian systems suffer from low yields, high production costs, and complex biosafety requirements • Bright Biotech replaces bioreactors with plants, using its proprietary chloroplast-engineering platform to express recombinant proteins efficiently and at scale RANIA DERANIEH, Chief Research Officer, **Bright Biotech** *Start Up Pitch 2:* **QUiCKRTM: 20-min Sequence Quantification For AVV & Edits QC** • QUiCKR's presentation will cover QC edits and cells in 20-minute sequences CHARLES BLANLUET, Founder, Chief Executive Officer, **QUiCKR Bio**	**Off The Shelf Cell Therapy For Type 1 Diabetes** • Allogeneic mesenchymal stromal cell therapy for halting type I diabetes disease progression • Single, outpatient based infusion of cells can dramatically alter disease progression for at least 5 years LINDSAY DAVIES, Chief Scientific Officer, **NextCell Pharma**	**Validation Of Potency Assays In Cell Therapy** High level description of various potency assays used in cell therapy and their validation strategies, including assay development and regulatory requirements KERRY SIEGER, Vice President of Global Quality Operations, **Immatics**	**New Viral Vectors For Next Generation Gene Therapy** • Immune silent gene delivery is essential • New viral vectors such as SV40 are the solution THIJS GERRITZEN, Director CMC Development, **Amarna Therapeutics**	**From Drop To Dose: Streamlining CAR-T Manufacturing With Whole Blood As The Starting Point** • A CAR-T targeting multiple solid cancers • Whole Blood as the starting material for the manufacture process • LEAN Manufacture with minimal manipulation model ARINDAM MITRA, Director of CMC, **Leucid Bio**

Q&A session & transition time between conference rooms

Day One | 11 November 2025

CELL CULTURE & BIOPROCESSING

TRACK 1: CELL LINE ENGINEERING ENSURING STABILITY, QUALITY & CLONALITY

CONFERENCE ROOM 1: MORANGIS

Seeing More At Day-0: Enhancing Monoclonality Assurance In Cell Line Development

This presentation demonstrates how a GMP-ready cell line development (CLD) platform was validated and documented using the multi-step artificial intelligence-assisted assurance of clonality with the fluorescence-enhanced Solentim® Ecosystem.

DR. SHEHNAZ AHMED-EHYAI, Key Account Manage EMEA Solentim, **Nova Biomedical**

TRACK 2: UPSTREAM BIOPROCESSING

CONFERENCE ROOM 2: BOURGOGNE

Decentralised Manufacturing Of CAR-T: Galapagos And NecstGen Partnership Case Study

The Galapagos decentralised manufacturing platform is pioneering in cell therapy production, delivering fresh, stem-like early memory cells with a vein-to-vein time of 7 days. By situating manufacturing sites close to cancer treatment centers, this approach overcomes critical barriers such as cryopreservation challenges, capacity limitations, and complex scheduling, which often extend treatment timelines and necessitate bridging therapies. Applying a Quality by Design approach combined with proprietary QC testing and release strategies, the platform ensures high-quality, consistent products ready for administration within one week, facilitating the advancement of potential best-in-class therapies addressing high unmet needs, supported by encouraging clinical data.

MELISSA VAN PEL, Head of Cell Therapy, **NecstGen**
GEMMA WARMERDAM, (Director) Head of EU Manufacturing, **Galapagos**

ADVANCED THERAPY DEVELOPMENT

TRACK 3: GENE THERAPY DISCOVERY & DEVELOPMENT

CONFERENCE ROOM 3: COGNAC

Unlocking Better Targets, Safer Therapies, & Higher Success Rates With 10x Single Cell And Spatial Multiomics

10x Genomics' Single Cell and Spatial solutions help researchers study disease with unmatched resolution and scale, generating data to validate targets and design therapies. From CAR T-cell response, resistance, and toxicity to cell interactions, functional states, and clonal diversity, 10x tools enable multiomic approaches that reveal mechanisms and accelerate translational applications in therapy development.

NICOLA CAHILL, Senior Science & Technology Advisor, **10x Genomics**

TRACK 4: CELL & GENE THERAPY ANALYTICS & QUALITY CONTROL

CONFERENCE ROOM 4: MUSCADET

Characterisation Of CAR-T Cells: Integrating Live-Cell Analysis And High-Throughput Cytometry

This presentation explores the characterisation of CAR-T cell therapies through live-cell analysis and High Throughput Screening by cytometry. It covers functional characterisation, and expansion optimisation, using case studies to illustrate dynamic insights and tools.

DARYL COLE, Scientist in Application Development, **Sartorius**

CELL & GENE THERAPY MANUFACTURING

TRACK 5: STRATEGIES & CHALLENGES FOR GENE THERAPY MANUFACTURING

CONFERENCE ROOM 5: ALSACE

Attendees are welcome to join co-located sessions

TRACK 6: SUPPLY CHAIN, LOGISTICS & COMMERCIALISATION

CONFERENCE ROOM 6: BOURG

Building Resilient Cryogenic Infrastructure For Laboratories

Explore strategies to build resilient cryogenic infrastructure in labs, ensuring sample integrity, regulatory compliance, and operational continuity under extreme conditions.

STEPHEN ROBINSON, Biomedical Product Specialist, **Air Products**

12:50

Q&A session & transition time between conference rooms

LUNCH BREAK & REFRESHMENTS

13:15 - 14:15

1-2-1 Meetings x3

Poster Displays

13:30 - 13:50 Fireside Chat on the 'Visionary Voices Stage' on Patient Advocacy & Patient Engagement. Conference Room 1: Morangis

Rachel Haines, Vice President, Clinical Development & Operations, Rinri Therapeutics

Day One | 11 November 2025

CELL CULTURE & BIOPROCESSING		ADVANCED THERAPY DEVELOPMENT		CELL & GENE THERAPY MANUFACTURING	
TRACK 1: CELL LINE ENGINEERING ENSURING STABILITY, QUALITY & CLONALITY **CONFERENCE ROOM 1: MORANGIS**	**TRACK 2: UPSTREAM BIOPROCESSING** **CONFERENCE ROOM 2: BOURGOGNE**	**TRACK 3: GENE THERAPY DISCOVERY & DEVELOPMENT** **CONFERENCE ROOM 3: COGNAC**	**TRACK 4: CELL & GENE THERAPY ANALYTICS & QUALITY CONTROL** **CONFERENCE ROOM 4: MUSCADET**	**TRACK 5: STRATEGIES & CHALLENGES FOR GENE THERAPY MANUFACTURING** **CONFERENCE ROOM 5: ALSACE**	**TRACK 6: SUPPLY CHAIN, LOGISTICS & COMMERCIALISATION** **CONFERENCE ROOM 6: BOURG**
Afternoon Track Chair: MALI ESKANDARPOUR, Senior Research Fellow, **University College London**	**Afternoon Track Chair:** HUAIYU YANG, Senior Lecturer, **Loughborough University**	**Afternoon Track Chair:** ERMIR KALAJ, Chief Executive Officer, **Cellula Therapeutics**	**Afternoon Track Chair:** NICOLE LUND, Senior Quality Control Director, **Bluerock Therapeutics**	**Afternoon Track Chair:** SVEN KILI, Partner, **Saisei Ventures**	**Afternoon Track Chair:** STEPHEN SULLIVAN, Director, **Lindville Bio**
Overcoming Bottlenecks In mAb Workflow Using An Automated Clone Screening System For Clone Selection The Cydem VT automated clone screening platform provides a high-throughput, integrated solution for Cell Line Development workflows. Automatisation of critical screening steps improves experimental consistency and contributes to the acceleration of biopharmaceutical development timelines. LUKAS BIALKOWSKI, Global Market Development Manager, **Beckman Coulter**	**Hamilton Unveils The Future Of CPP Monitoring** Join Hamilton Process Analytics as we reveal our latest breakthrough in real-time monitoring of Critical Process Parameters (CPPs) for cell culture. Building on our legacy of pioneering in-line sensor technologies, we continue to drive smarter, more efficient bioprocessing. You'll have the chance to see our newest innovative process sensors—live. Stay tuned for more. GIOVANNI CAMPOLONGO, Senior Market Segment Manager Process Analytics, **Hamilton**	**The Next Advancement In AAV Characterisation: Empty-Full Assessment With Droplet Digital PCR** Droplet Digital PCR (ddPCR) offers precise, absolute quantification of nucleic acids, making it ideal for Cell & Gene Therapy. Bio-Rad's Vericheck line of ddPCR kits provides critical quality control for cell and gene therapy manufacturing workflows. ELIZABETH BOWLER, Field Application Specialist for Genomics (UK South), **Bio-Rad Laboratories**	**Precision Characterisation Of Complex Modalities: Unlocking AAV, LNP, And Vaccine Insights With Charge Detection Mass Spectrometry** Discover how Waters Xevo CDMS enables precise, high-throughput characterisation of large, complex biologics—empowering gene therapy, vaccine, and biotherapeutic development from discovery to quality control. BEN WILKES, Principal Biologics Market Development Manager, **Waters**	**Viral Vector Production Platform Innovations Enable More Cost-Effective CGT Manufacturing** Discover how Minaris Advanced Therapies' XOFLX™, TESSA®, and cargo gene silencing technologies are transforming viral vector manufacturing—enhancing productivity, quality, and cost-efficiency—plus hear a case study on advancing TESSA® from innovation to manufacturing platform. QIAN LIU, Head of Plasmid Engineering and LVV, **Minaris Advanced Therapies**	*Attendees are welcome to join co-located sessions*

14:15

Q&A session & transition time between conference rooms

Day One | 11 November 2025

CELL CULTURE & BIOPROCESSING		ADVANCED THERAPY DEVELOPMENT		CELL & GENE THERAPY MANUFACTURING	
TRACK 1: CELL LINE ENGINEERING ENSURING STABILITY, QUALITY & CLONALITY **CONFERENCE ROOM 1: MORANGIS**	**TRACK 2: UPSTREAM BIOPROCESSING** **CONFERENCE ROOM 2: BOURGOGNE**	**TRACK 3: GENE THERAPY DISCOVERY & DEVELOPMENT** **CONFERENCE ROOM 3: COGNAC**	**TRACK 4: CELL & GENE THERAPY ANALYTICS & QUALITY CONTROL** **CONFERENCE ROOM 4: MUSCADET**	**TRACK 5: STRATEGIES & CHALLENGES FOR GENE THERAPY MANUFACTURING** **CONFERENCE ROOM 5: ALSACE**	**TRACK 6: SUPPLY CHAIN, LOGISTICS & COMMERCIALISATION** **CONFERENCE ROOM 6: BOURG**
INTERACTIVE ***Roundtable Discussion:*** IND Enabling Studies On Immunotoxicity For Large Molecules • Should we move toward mechanism-based, risk-driven study designs instead of standard checklists? • Are there validated strategies to distinguish PD effects vs. adverse immune activation? • How do emerging modalities (CAR-T, bispecifics, immune agonists) challenge traditional frameworks?	INTERACTIVE ***Panel Discussion:*** Innovations & Challenges In Upstream Bioprocessing: Navigating The Future Of Cell Culture & Bioprocessing • Cell line development & optimisation • Automation & process control • Stability & process control	***Focused Stem Cells Session*** **Repairing Vision In Retinitis Pigmentosa Patients Going Blind** Alder Therapeutics develops regenerative cell therapies for diseases with high unmet need. The presentation will concentrate on the lead program ALD01, which is aimed at improving vision in Retinitis Pigmentosa patients, 98% of whom are without any treatment options today. Alder's patented manufacturing platform uses a unique and exclusive combination of extracellular matrix proteins that make the manufacturing process extremely simple, short and cheap.	INTERACTIVE ***Panel Discussion:*** Navigating The Analytical Lifecycle: Strategic Management For Streamlined CGT Product Development • End-to-end analytical strategy • Data-drive decision making • Risk management & quality control	INTERACTIVE ***Panel Discussion:*** Sustainability & Outsourcing In Cell & Gene Therapy Manufacturing • Price considerations • Facilitating sustainability • Sustainability at clinical stage	**Gene Therapy Supply With Weight-Based Dosing** REGENXBIO's presentation on AAV gene therapy supply highlights challenges in weight-based dosing where multi-vial kits increase lead time and cost. A desired hybrid kitting model aims to decrease lead time and cost, while maintaining product quality and serialisation compliance.
14:40 **Moderator:** MALI ESKANDARPOUR, Senior Research Fellow, **University College London**	**Moderator:** DARIA MARSH, Head of Bioprocessing, **Cell & Gene Catapult** **Panellists** AYCA CETINKAYA, Senior Scientist, **AstraZeneca** MARCIA MATA, Programme Head of Automation, **Cell and Gene Therapy Catapult** RICHARD HAMMOND, Chief Technical Officer, **Fluidic Sciences** ROELOF RONGEN, Co-Founder & Board Director, **AeirBio**	KRISTIAN TRYGGVASON, Co-Founder & Chief Executive Officer, **Alder Therapeutics**	**Moderator:** TERRI GASKELL, Chief Technology Officer, **Rinri Therapeutics** **Panellists:** NICOLE LUND, Senior Quality Control Director, **Bluerock Therapeutics** MITCHELL BRAAM, Scientist, **Cell and Gene Therapy Catapult** JON BEAMAN, Deputy Director Innovative Medicines, **MHRA**	**Moderator:** TIFFANY RAU, Professor Biochemistry & Cell Biology, **University College Cork** **Panellists:** THIJS GERRITZEN, Director CMC Development, **Amarna Therapeutics** LILIAN HOOK, Director Cell, Apheresis & Gene Therapies, **NHS Blood and Transplant**	MATT STONE, Director of Supply Chain, **REGENXBIO**

Q&A session & transition time between conference rooms

Day One | 11 November 2025

CELL CULTURE & BIOPROCESSING		ADVANCED THERAPY DEVELOPMENT		CELL & GENE THERAPY MANUFACTURING	
TRACK 1: CELL LINE ENGINEERING ENSURING STABILITY, QUALITY & CLONALITY **CONFERENCE ROOM 1: MORANGIS**	**TRACK 2: UPSTREAM BIOPROCESSING** **CONFERENCE ROOM 2: BOURGOGNE**	**TRACK 3: GENE THERAPY DISCOVERY & DEVELOPMENT** **CONFERENCE ROOM 3: COGNAC**	**TRACK 4: CELL & GENE THERAPY ANALYTICS & QUALITY CONTROL** **CONFERENCE ROOM 4: MUSCADET**	**TRACK 5: STRATEGIES & CHALLENGES FOR GENE THERAPY MANUFACTURING** **CONFERENCE ROOM 5: ALSACE**	**TRACK 6: SUPPLY CHAIN, LOGISTICS & COMMERCIALISATION** **CONFERENCE ROOM 6: BOURG**
Lost In Translation? Patient-Centric Cell Models Paving The Way For Drug Discovery • The Global Cell Bank at AstraZeneca is increasing project teams' accessibility to patient-centric organoid models, that better recapitulate human disease microenvironments for drug discovery • CRISPR and high throughput compound screening in normal and cancer organoids are enabling target identification and validation for patient stratification, safety, and combination studies GEMMA EVERITT, Senior Research Scientist, UK Cell Culture & Banking, **AstraZeneca**	**Single-Use Bioreactors And Digital Solutions For A Seamless Bioprocessing** • Innovative cell retention device combined with single-use bioreactors streamlines continuous bioprocessing • Cloud-based solution boost efficiency in data management and analysis with real-time monitoring, secure data storage, and advanced analytics IGOR VASSILEV, Application Laboratory Manager, **Eppendorf**	**Translating Podocyte-Targeting Gene Therapy To Patients With Kidney Disease** • Purespring is a precision nephrology company leveraging a unique podocyte-targeting AAV gene therapy platform to treat kidney disease • Three products are under development including the lead product PS-002, which is about to enter first in human trials for the treatment of IgA Nephropathy (IgAN) • PS-002 preclinical efficacy, safety and biodistribution has been demonstrated in translationally relevant IgAN mouse disease models and clinically translatable large animal species JAMES MATTHEWS, Senior Scientist, **PureSpring Therapeutics**	**Development And Manufacture Of Physical Standards For Cell And Gene Therapies** • Introduction to the MHRA Science Campus • Discussing the need for cell and gene therapy standards • The complexity of designing and developing standards • Past and current research focus of the MHRA science campus gene therapy team CLAIRE KERRIDGE, Head Of Gene Therapy, **MHRA**	INTERACTIVE ***Panel Discussion:*** **Cell & Gene Therapy Investment In A Challenging Economy: Navigating Risks & Opportunities** • Navigating the investment landscape: emerging trends, hotspots & redflags • Overcoming funding bottlenecks in a competitive market • Finding the right funding path for CGT innovation • Co-ordinating business strategy with IP strategy • Market landscape from early to late-stage investment **Moderator:** KATY TROST, Chief Executive Officer Coach & Advisor/Founder, **Pera CEO Network** **Panellists:** CORNEL CHIRIAC, Investment Director, **M&G Crossover Fund** CLAIRE IRVINE, European and UK Patent Attorney of Counsel, **Beck Greener** SVEN KILI, Partner, **Saisei Ventures**	**Oncolytic Viruses - From Development To Clinical Supply** • Development of a manufacturing process for oncolytic viruses • Scale-up and transfer to Clinical Supply facility • Challenges for shipping under deep frozen conditions TAMARA STRAUB, Senior Scientist, **Boehringer Ingelheim**

15:05

Q&A session & transition time between conference rooms

BROCHURE CONTENTS

Welcome

Benefits of Attending

Sponsors

Special Event Features

Agenda at a Glance

Keynote Speakers

Spotlight Speakers

All Speakers

Full Programme: Pre-Event Day

Full Programme: Day One

Full Programme: Day Two

Venue Information

Book Now

Day One | 11 November 2025

	CELL CULTURE & BIOPROCESSING		ADVANCED THERAPY DEVELOPMENT		CELL & GENE THERAPY MANUFACTURING	
	TRACK 1: CELL LINE ENGINEERING ENSURING STABILITY, QUALITY & CLONALITY CONFERENCE ROOM 1: MORANGIS	TRACK 2: UPSTREAM BIOPROCESSING CONFERENCE ROOM 2: BOURGOGNE	TRACK 3: GENE THERAPY DISCOVERY & DEVELOPMENT CONFERENCE ROOM 3: COGNAC	TRACK 4: CELL & GENE THERAPY ANALYTICS & QUALITY CONTROL CONFERENCE ROOM 4: MUSCADET	TRACK 5: STRATEGIES & CHALLENGES FOR GENE THERAPY MANUFACTURING CONFERENCE ROOM 5: ALSACE	TRACK 6: SUPPLY CHAIN, LOGISTICS & COMMERCIALISATION CONFERENCE ROOM 6: BOURG
15:30	**Multiparameter Sensor For Shake Flasks: Removing Black Boxes For Improved Bioprocess Development** This presentation highlights how sbi's cutting-edge sensors and software can be used to create bioreactor-like shake flasks, enabling actionable insights into your bioprocess when and where it matters most. HENDRIK SCHMIDT, Regional Sales Lead Western Europe, **SBI Scientific Bioprocessing**	**Accelerate The Scale-Up To Clinical Phase With Animal-Free Solutions - Optimising Cell Culture Performance And Viral Vector Titers With Recombinant Insulin And TrypsiNNex®** The transition from research-grade to GMP-compliant cell culture systems requires replacing animal-derived components with defined animal-free alternatives. This talk will show how the optimisation of two animal-free solutions—Recombinant Insulin and TrypsiNNex®—can improve cell culture performance while accelerating clinical scale-up across multiple therapeutic applications. CHANTALE JULIEN, Global Product Manager, **Novo Nordisk**	*Start Up Pitch:* **CellForgeTM A Digital Infrastructure for Human Cell Manufacturing** PHILIPPE CHEMLA, Chief Business Officer, **iOrgan Bio**	**Connecting Prodigy And MACSQuant® Analytics Across The TCT Workflow** Discover how Miltenyi Biotec's CliniMACS Prodigy® platform streamlines the TCT process through automation, while the MACSQuant® Analyser provides precise, real-time in-process analytics. Together, they deliver an end-to-end solution for cell therapy manufacturing—enabling consistent, data-driven quality control from cell modification to final formulation. EREN COSTUE, Clinical Application Specialist **Miltenyi Biotec**	**Key Considerations Of Plasmid DNA Manufacturing For Viral Vector Production** CoJourney's CEO shares how the Zero-Chrom® plasmid platform and high-titer AAV manufacturing boost yield and purity while cutting cost per dose by ~100×–1,500×, with GMP capacity and fast turnaround to accelerate gene therapy programs. LIJUN WANG, Founder & Chief Executive Officer, **CoJourney**	*Attendees are welcome to join co-located sessions*
15:55 - 17:15	AFTERNOON BREAK & REFRESHMENTS					
	1-2-1 Meetings x4		Poster Displays		**16:05 - 16:25** Fireside Chats on the 'Visionary Voices Stage': CGT Development & Manufacturing. Conference Room 1: Morangis Terri Gaskell, Chief Technology Officer, Rinri Therapeutics	

Day One | 11 November 2025

	CELL CULTURE & BIOPROCESSING		ADVANCED THERAPY DEVELOPMENT			CELL & GENE THERAPY MANUFACTURING
	TRACK 1: CELL LINE ENGINEERING ENSURING STABILITY, QUALITY & CLONALITY CONFERENCE ROOM 1: MORANGIS	TRACK 2: UPSTREAM BIOPROCESSING CONFERENCE ROOM 2: BOURGOGNE	TRACK 3: GENE THERAPY DISCOVERY & DEVELOPMENT CONFERENCE ROOM 3: COGNAC	TRACK 4: CELL & GENE THERAPY ANALYTICS & QUALITY CONTROL CONFERENCE ROOM 4: MUSCADET	TRACK 5: FOCUSED STEM CELL SESSION CONFERENCE ROOM 5: ALSACE	TRACK 6: SUPPLY CHAIN, LOGISTICS & COMMERCIALISATION CONFERENCE ROOM 6: BOURG
17:15	INTERACTIVE ***Roundtable Discussion:*** **Novel Formats For Cell Line Engineering** • CRISPR-based multiplexed editing platforms • Synthetic chromosome & episomal vector systems • Cell free systems • Automated microfluidic & AIdriven screening **Moderators:** TIFFANY RAU, Professor Biochemistry & Cell Biology, **University College Cork** JOE BETTS-LACROIX, Chief Executive Officer**, Retro Biosciences**	**Towards Commercialisation Of ATMP Manufacturing Through Scaling And Automation** • Exploring industrialisation of ATMP manufacturing through scaling and automation • Focus on scale-up and scale-out strategies for iPSC and CAR-T therapies • Showcasing case studies and innovations improving process consistency, reliability, and scalability • Highlighting cost-reduction and commercialisation pathways for next-generation cell therapies MARCIA MATA, Programme Head of Automation, **Cell & Gene Therapy Catapult**	**Towards Intensified Continuous Manufacturing For Scalable rAAV Production** • Next-gen rAAV manufacturing: intensified, continuous manufacturing for affordable, scalable, high-quality supply • How we get there: upstream perfusion high cell density & continuous harvest; continuous downstream processing for yield/purity; and the shift to PAT, digital twins, and automation MARIA BARREIRA GONZALEZ, Programme Head of Gene Modification, **Cell & Gene Therapy Catapult**	**Establishing Comprehensive Analytical Development Program For Autoimmune Diseases** • Phase-appropriate and risk-based method development, qualification and validation • Maximising analytics work to reach first in clinics in the resource constrained biotech environment CHIEN-CHUNG CHEN, Senior Director, Analytical Development, **Cabaletta Bio**	***Focused Stem Cells Session*** **Stem Cell-Based Gene Therapy For Recombinase Deficient-SCID** A clinical trial for RAG1-SCID has been initiated, while for RAG2 a clinical batch vector has been generated in preparation for a Phase/II trail in 2024. Five patients have thus far been included in the RAG1-SCID trial, with excellent clinical and immunological results. Importantly, we aim for multicentre, international trials with various clinical sites in Europe, Asia and Australia. For several countries, including Spain, Poland and Turkey, clinical centres have been added, from where patients' stem cells will be sent to Leiden, genetically modified and after QC returned to these centres as cryopreserved IMP. Thus, the paradigm of this consortium (cells travel, while patients stay home) has become realistic and should be of use for other gene therapy trials for rare diseases. FRANK STAAL, Professor of Stem Cell Biology, Leiden, **University Medical Center**	INTERACTIVE ***Panel Discussion:*** **Collaboration Within CGT Supply Chain** • Building a collaborative ecosystem for CGT • Bridging clinical & commercial gaps • Designing for a circular economy in CGT • Strengthening supply chain resilience • Futureproofing through collaboration **Moderator:** OLGA BUKATOVA, Associate Director, **Azenta** **Panellists:** RICHARD FORSEY, Project Specialist, **NHS Blood and Transplant** MATT STONE, Director of Supply Chain, **RegenxBio**

Q&A session & transition time between conference rooms

Day One | 11 November 2025

	CELL CULTURE & BIOPROCESSING		ADVANCED THERAPY DEVELOPMENT			CELL & GENE THERAPY MANUFACTURING
	TRACK 1: CELL LINE ENGINEERING ENSURING STABILITY, QUALITY & CLONALITY CONFERENCE ROOM 1: MORANGIS	TRACK 2: UPSTREAM BIOPROCESSING CONFERENCE ROOM 2: BOURGOGNE	TRACK 3: GENE THERAPY DISCOVERY & DEVELOPMENT CONFERENCE ROOM 3: COGNAC	TRACK 4: CELL & GENE THERAPY ANALYTICS & QUALITY CONTROL CONFERENCE ROOM 4: MUSCADET	TRACK 5: FOCUSED STEM CELL SESSION CONFERENCE ROOM 5: ALSACE	TRACK 6: SUPPLY CHAIN, LOGISTICS & COMMERCIALISATION CONFERENCE ROOM 6: BOURG
17:40	INTERACTIVE ***Roundtable Discussion Continued:*** Novel Formats For Cell Line Engineering • CRISPR-based multiplexed editing platforms • Synthetic chromosome & episomal vector systems • Cell free systems • Automated microfluidic & AIdriven screening **Moderator:** TIFFANY RAU, Professor Biochemistry & Cell Biology, **University College Cork** JOE BETTS-LACROIX, Chief Executive Officer, **Retro Biosciences**	**Metabolic Modelling-Driven Bioprocess Optimisation: Real-World Applications In Advanced Biologics Manufacturing** At this year's conference, Dr. Cankorur-Cetinkaya will share perspectives on utilising metabolic modelling approaches to drive media and feed development, highlighting how these tools can accelerate process optimisation for novel modalities. AYCA CETINKAYA, Senior Scientist, **AstraZeneca**	**Cell & Gene Development Strategies** SaxoCell® will be presented by its co-speaker Professor Martin Bornhäuser, also head oft he Department of Haematology and Medical Oncology, University Hospital Dresden. Saxocell® is a precision-therapy cluster within the Initiative"Clusters4Future" funded by the German Federal Ministry for Research, Technology and Space Travel. Located in Saxony (Dresden/ Leipzig/Chemnitz), its goal is to develop scalable, safe and cost-effective cell and gene therapies ("living drugs") — mostly allogeneic and off-the-shelf — for difficult-to-treat and rare diseases. SaxoCell also aims to build a strong regional biotech value-chain, foster collaboration between research, clinic and industry, and strengthen Saxony's position as a leading hub for advanced therapy medicinal products (ATMPs). MARTIN BORNHÄUSER, Professor, **King's College London**	**Non-Viral Delivery Of CRISPRa Tools For Scalable Directed Differentiation Of Induced Pluripotent Stem Cells** We developed an innovative CRISPR-mediated transcriptional activation system combined with non-viral delivery to establish a scalable forward programming workflow. Our approach leverages the delivery of catalytically dead Cas9-VPR mRNA and four CRISPR guide RNA pools targeting known critical haematopoietic transcription factors, driving differentiation toward haemato-endothelial progenitors. MITCHELL BRAAM, Scientist, **Cell and Gene Therapy Catapult**	*Attendees are welcome to join co-located sessions*	*Attendees are welcome to join co-located sessions*
18:05	**CLOSE OF DAY ONE** Cell & Gene Fronties on Ice: Drinks Reception - Opened by Erin Harris, Chief Editor, Cell & Gene Meet peers, pioneers, and innovators driving advances in cell and gene therapy - all in a vibrant, informal setting designed to foster meaningful connections. 					

Day Two | 12 November 2025

Keynote Address

Conference Room: Morangis - Visionary Voices Stage

Morning Roundtables with Refreshments - Exhibition Room: Morangis

08:30

ROUNDTABLE DISCUSSION 1: **Future Bullet Proof CAR-T Manufacturing**

- Small to large scale processes
- Patient's experience
- Process closure and automation

Moderator: SARAH SNYKERS, Senior Director of Operations, **Legend Biotech**

ROUNDTABLE DISCUSSION 2: **Regulatory Considerations**

- IP challenges
- Impact on advanced therapies

Moderator: LUCY WILLIAMS, Partner, European & UK Patent Attorney, **J A Kemp**

ROUNDTABLE DISCUSSION 3: **Tissue Engineering/Stem Cell Development**

- Translating stem cell advances into aging therapies
- Overcoming scale-up & regulatory hurdles

Moderator: JOE BETTS-LACROIX, Chief Executive Officer, **Retro Biosciences**

Event Moderator's Welcome: Erin Harris, Chief Editor, Cell & Gene

09:00

KEYNOTE ADDRESS: **Smarter, Faster, Healthier: Making The Most Of AI & Bioengineering Breakthroughs**

Exploring how AI and emerging bioengineering technologies are enabling more sensitive diagnostics, targeted and personalised nanomedicine, and advanced in vitro models that better mimic human physiology to drive deeper insights and more effective therapies

DAME MOLLY STEVENS, John Black Professor of Bionanoscience, **University of Oxford**

CELL CULTURE & BIOPROCESSING		ADVANCED THERAPY DEVELOPMENT		CELL & GENE THERAPY MANUFACTURING
TRACK 1: GENERATION & VALIDATION OF PRE-CLINICAL MODELS & STEM CELLS **CONFERENCE ROOM 1: MORANGIS**	**TRACK 2: DOWNSTREAM BIOPROCESSING** **CONFERENCE ROOM 2: BOURGOGNE**	**TRACK 3: CELL THERAPY DISCOVERY & DEVELOPMENT** **CONFERENCE ROOM 3: COGNAC**	**TRACK 4: CLINICAL DEVELOPMENT & CLINICAL TRIALS FOR CELL & GENE THERAPIES** **CONFERENCE ROOM 4: MUSCADET**	**TRACK 5: STRATEGIES FOR CELL THERAPY MANUFACTURING** **CONFERENCE ROOM 5: ALSACE**
Morning Track Chair: LEILA ABBAS, Preclinical Lead, **Rinri Therapeutics**	**Morning Track Chair:** JULIE BEAUDET, Chemistry, Manufacturing, & Control Senior Staff Scientist, **Regeneron**	**Morning Track Chair:** TERRI GASKELL, Chief Technology Officer, **Rinri Therapeutics**	**Morning Track Chair:** PANTELI THEOCHAROUS, Chairman of the Board of Directors, TMOIF & Chief Executive Officer, **VectorGen**	**Morning Track Chair:** SABINA LANCASTER, Technical Programme Head, **Legend Bio**
The 3D-IV Project: Novel Bioprinters For 3D In Vitro Models The 3D-IV project focussed on accelerating the adoption of novel 3D bioprinting techniques for in vitro models through creating a new multi-mode bioprinter then demonstrating use in the creation of a range of advanced in vitro models, covering leukaemia, liver cancer, embryonic development, osteoarthritis and cardiac drug safety assessment. KENNY DALGARNO, Professor, **Newcastle University**	**Strategies For Establishing Impurity Clearance & Assessment** • Impurity testing, development studies, or risk assessment • Which is the answer? JULIE BEAUDET, Chemistry, Manufacturing, & Control Senior Staff Scientist, **Regeneron**	**Using RNA To Program In Vivo & Ex Vivo Therapies** At SymphoRNA, we harness the synergistic power of biological pathways by using multiple RNAs - because one target is rarely enough. I will discuss why it's essential to move beyond single-therapy approaches, and how precisely mapping the 'knowns' of these pathways enables us to tackle the previously undruggable. By doing so, we can develop therapeutics that target exactly what matters. RUTH FARAM, Co-Founder & Chief Scientific Officer, **SymphoRNA**	**Translating A Regenerative Cell Therapy For Hearing Loss From Bench To Bedside** Rinri Therapeutics' lead product, Rincell-1, is a first-in-class regenerative cell therapy, consisting of a population of otic neural progenitor cells capable of becoming mature auditory neurons, restoring hearing in patients with neural hearing loss. This presentation will provide an overview of the journey into a clinical phase company with approval granted to conduct a FIH randomised open label trial to assess the safety and feasibility of Rincell-1, compared to cochlear implantation alone. RACHEL HAINES, Vice President, Clinical Development and Operations, **Rinri Therapeutics**	**Designing Large Scale Cell Therapies For Real-World Access: Lessons From CORDStrom** • Reframing the *autologous vs allogeneic* debate towards real-world scenarios, patient access, and clinical impact • Pooled donor, umbilical cord–derived MSC platform design (CORDStrom) as a model for manufacturing reproducibility and commercial readiness • Phase-appropriate GMP and bioprocess strategy, including the transition from 2D to 3D microcarrier systems while maintaining functional identity and CQAs • Operational feasibility for global supply, focusing on clinic suitability and sustainable bioprocessing approaches BEN WEIL, Chief Operating Officer & Chief Manufacturing Officer, **INmune Bio**

09:25

Q&A session & transition time between conference rooms

Day Two | 12 November 2025

	CELL CULTURE & BIOPROCESSING		ADVANCED THERAPY DEVELOPMENT		CELL & GENE THERAPY MANUFACTURING
	TRACK 1: GENERATION & VALIDATION OF PRE-CLINICAL MODELS & STEM CELLS CONFERENCE ROOM 1: MORANGIS	TRACK 2: DOWNSTREAM BIOPROCESSING CONFERENCE ROOM 2: BOURGOGNE	TRACK 3: CELL THERAPY DISCOVERY & DEVELOPMENT CONFERENCE ROOM 3: COGNAC	TRACK 4: CLINICAL DEVELOPMENT & CLINICAL TRIALS FOR CELL & GENE THERAPIES CONFERENCE ROOM 4: MUSCADET	TRACK 5: STRATEGIES FOR CELL THERAPY MANUFACTURING CONFERENCE ROOM 5: ALSACE
09:50	**CO2 Stability Inside The Cell Culture Vessel Matters: What Really Happens When The Door Opens** This talk shows how repeated and automated door openings in CO2 incubator shakers affect CO2 levels inside 600 mL TPP tubes, revealing that vessel conditions stay remarkably stable despite steep and rapid chamber fluctuations. DAVID FLITSCH, Head of Application Support, **Kuhner Shaker**	*Attendees are welcome to join co-located sessions*	**Enabling Ultra-High Throughput Screening For Therapeutic Cell Engineering And Selection Eith Cyto-Mine® Chroma** Development of CAR-T therapies relies on two core processes: high-efficiency gene editing and selection of edited cells with the required functional capabilities from a population. In this talk we will introduce Cyto-Mine® Chroma, a novel platform for assessing cell function and selecting high-performing cells quickly and easily. We will also introduce a new Cyto-Mine upgrade module in development to allow high-throughput gene editing workflows and cell-cell functional interaction studies. RICHARD HAMMOND, Chief Technical Officer, **Fluidic Sciences**	*Attendees are welcome to join co-located sessions*	**From Bench To Batch: Scalable Automated Solutions For Cell Therapy Manufacturing And QC Assay Testing** An overview of a collaboration with Guy's St Thomas Hospital and Thermo Fisher Scientific where automation of critical processing steps and the rapid development of a residual bead assay has been implemented following a change in reagent for the stimulation of T-Regs. SANDEEP KUMAR, Head of Advanced Therapy Production, Guy's and St Thomas' NHS Foundation Trust, **Thermo Fisher Scientific** KATRINA TODD, Senior Quality Control Scientist, **Thermo Fisher Scientific**
10:15 - 11:35	MORNING COFFEE & REFRESHMENTS				
	1-2-1 Meetings x4			Poster Displays	

Day Two | 12 November 2025

CELL CULTURE & BIOPROCESSING		ADVANCED THERAPY DEVELOPMENT		CELL & GENE THERAPY MANUFACTURING
TRACK 1: GENERATION & VALIDATION OF PRE-CLINICAL MODELS & STEM CELLS CONFERENCE ROOM 1: MORANGIS	**TRACK 2: DOWNSTREAM BIOPROCESSING** CONFERENCE ROOM 2: BOURGOGNE	**TRACK 3: CELL THERAPY DISCOVERY & DEVELOPMENT** CONFERENCE ROOM 3: COGNAC	**TRACK 4: CLINICAL DEVELOPMENT & CLINICAL TRIALS FOR CELL & GENE THERAPIES** CONFERENCE ROOM 4: MUSCADET	**TRACK 5: STRATEGIES FOR CELL THERAPY MANUFACTURING** CONFERENCE ROOM 5: ALSACE
Turning Images Into Numbers: Leveraging High-Throughput Imaging For Data-Driven Decision Making In Clonal Cell Line Development High-throughput imaging with SYNENTEC's CELLAVISTA and NYONE transforms cell line development - automating single-cell isolation, growth, and clonality analysis for data-driven decisions that elevate reliability, speed and colony yield.	INTERACTIVE **From Research To GMP: Strengthening Reagent Quality And QC In CGT Manufacturing** **Presentation 1: Solutions To Enable Safe And Scalable Bioproduction**	**Assessment Of Tumour Cell Susceptibility To Killing By Antigen-Specific And Nonspecific CD8+T Cells** The success of immune-checkpoint blockade highlights CD8+T cells as central to tumour control, yet mechanisms of cancer cell elimination remain unclear. Tumours escape antigen-specific CTL killing via MHC-I loss or defective antigen processing. In contrast, cytokine-licensed antigen-unspecific CD8+T cells can bypass this limitation. We aim to define how tumour susceptibility differs between these killing modes to tailor strategies that enhance effective CD8+T cell tumour killing across different cancer types.	*Attendees are welcome to join co-located sessions*	**One Reactor To Rule Them All: How A Novel Bionic Bioreactor Cultivates Sensitive Stem- & Immune-Cells From 150mL To 200L** We present different fields of application of our bionic membrane bioreactor after one year of market entry: IPSC, MSC, (i)NK, Organoids, EVs, CHO & HEK. Furthermore, we show our new incubator-based solution and glimpse on our upcoming developments.
11:35				
DR SEBASTIAN KOLLENDA-STRUNK, Application Specialist, **Synentech**	HUI YU, Field Application Development Director, **ACROBiosystems**	MICHAEL DUDEK, Reserach Group Leader, **Nanion**		PATRICK BONGARTZ, Chief Executive Officer, & Co-Founder, **Biothrust**
Q&A session & transition time between conference rooms			*Q&A session & transition time between conference rooms*	

Day Two | 12 November 2025

	CELL CULTURE & BIOPROCESSING		ADVANCED THERAPY DEVELOPMENT		CELL & GENE THERAPY MANUFACTURING
	TRACK 1: GENERATION & VALIDATION OF PRE-CLINICAL MODELS & STEM CELLS CONFERENCE ROOM 1: MORANGIS	TRACK 2: DOWNSTREAM BIOPROCESSING CONFERENCE ROOM 2: BOURGOGNE	TRACK 3: CELL THERAPY DISCOVERY & DEVELOPMENT CONFERENCE ROOM 3: COGNAC	TRACK 4: CLINICAL DEVELOPMENT & CLINICAL TRIALS FOR CELL & GENE THERAPIES CONFERENCE ROOM 4: MUSCADET	TRACK 5: STRATEGIES FOR CELL THERAPY MANUFACTURING CONFERENCE ROOM 5: ALSACE
12:00	**Scaling Up Complex Organoid Models: Challenges And Solutions** Using vascularised hair-bearing skin organoids supplemented with macrophages as a case study, I'll share the key challenges in scaling complex disease models and the solutions we developed to overcome them. These examples will reflect common hurdles in scaling advanced organoid research and offer practical strategies for other complex cell systems. MARYNA PANAMAROVA, 3D Cellular Modelling Specialist, Cellular Operations, **Wellcome Sanger Institute**	INTERACTIVE **From Research To GMP: Strengthening Reagent Quality And QC In CGT Manufacturing** **Presentation 2: Phase III Study For Post-acute Myocardial Infarction** IBON GARITAONANDIA, Chief Scientific Officer, **Cellprothera**	**An Encapsulation Platform For Development And Scalable Manufacturing Of Cell-Based Therapies** • Cell encapsulation for expansion, differentiation and scalable and manufacturing • Engineering synthetic niches via encapsulation of Human Pluripotent Stem Cells • Modelling stem cell biology, structure formation and mechanics PETER ANDERSEN, Chief Research & Development Officer, **TreeFrog Therapeutics**	INTERACTIVE ***Panel Discussion:*** Experiences In Executing Cell & Gene Therapy Studies With Patient Engagement In Mind • What is effective and what is not • Applications of filing R&D – how this process works in different geographies • Patent engagement **Moderator:** PANTELI THEOCHAROUS, Chairman of the Board of Directors, TMOIF & Chief Executive Officer, **VectorGen** **Panellists:** RACHEL HAINES, Vice President, Clinical Development and Operations, **Rinri Therapeutics** JOANNA BREWER, Former Chief Scientific Officer, **Adaptimmune** NITIN PATEL, Vice President Of Late-Stage Clinical Development, **Legend Biotech** DIANA HERNANDEZ, Director of Immune and Advanced Therapies, **Anthony Nolan**	INTERACTIVE ***Panel Discussion:*** Developing & Manufacturing Cell Therapies In Large Scale • Utilisation of tools – isolators, cell selection technologies • Scaling up technologies **Moderator:** ERMIR KALAJ, Chief Executive Officer, **Cellula Therapeutics** **Panellists:** BEN WEIL, Chief Operating Officer & Chief Manufacturing Officer, **INmune Bio** SABINA LANCASTER, Technical Programme Head, **Legend Bio** GEORGE PROUT, Senior Field Applications Scientist, **Thermo Fisher Scientific**

Q&A session & transition time between conference rooms

Book Now

LinkedIn
@NextGenBiomedOG

Day Two | 12 November 2025

CELL CULTURE & BIOPROCESSING		ADVANCED THERAPY DEVELOPMENT		CELL & GENE THERAPY MANUFACTURING
TRACK 1: GENERATION & VALIDATION OF PRE-CLINICAL MODELS & STEM CELLS CONFERENCE ROOM 1: MORANGIS	**TRACK 2: DOWNSTREAM BIOPROCESSING** CONFERENCE ROOM 2: BOURGOGNE	**TRACK 3: CELL THERAPY DISCOVERY & DEVELOPMENT** CONFERENCE ROOM 3: COGNAC	**TRACK 4: CLINICAL DEVELOPMENT & CLINICAL TRIALS FOR CELL & GENE THERAPIES** CONFERENCE ROOM 4: MUSCADET	**TRACK 5: STRATEGIES FOR CELL THERAPY MANUFACTURING** CONFERENCE ROOM 5: ALSACE
Media Optimisation For Increasing Biomass Production From Fish Cells BLUU GmbH is a cultivated seafood company primarily focusing on developing premium seafood products from cultivated fish cells for human consumption. To make the products a scalable and an economically viable option, increasing the biomass content of the cells is a key area that we are currently working towards. • This presentation will give insights on medium optimisation and feeding strategy to increase the biomass content of fish cells • Additionally, the presentation will also highlight some of the differences in the cellular characteristics and approaches we utilise to increase the biomass in different salmonoid species and the challenges LINN MARIE KREINS, Scientist, **Bluu Seafood**	INTERACTIVE **From Research To GMP: Strengthening Reagent Quality And QC In CGT Manufacturing** **Presentation 3: De-Risking The CAR T Pipeline: Implementing Custom Antibody Solutions For Phase-Appropraite Quality Control** BIOSYSTEMS Acro CARAUGH JANE ALBANY, Senior Scientist, **Autolus**	**Ongoing CAR-T Development** • Reducing the risk of clinical failure starting from the design of the Lead Candidate • CAR-T Development steps • Harnessing the commercial value in early stages ERMIR KALAJ, Chief Executive Officer, **Cellula Therapeutics**	INTERACTIVE ***Panel Discussion Continued:*** **Experiences In Executing Cell & Gene Therapy Studies With Patient Engagement In Mind** • What is effective and what is not • Applications of filing R&D – how this process works in different geographies • Patent engagement **Moderator:** PANTELI THEOCHAROUS, Chairman of the Board of Directors, TMOIF & Chief Executive Officer, **VectorGen** **Panellists:** RACHEL HAINES, Vice President, Clinical Development and Operations, **Rinri Therapeutics** JOANNA BREWER, Former Chief Scientific Officer, **Adaptimmune** NITIN PATEL, Vice President Of Late-Stage Clinical Development, **Legend Biotech** DIANA HERNANDEZ, Director of Immune and Advanced Therapies, **Anthony Nolan**	**CAR-T EU Manufacturing Footprint: From Start-Up To Commercial Scale Up** • Clinical and commercial CAR-T manufacturing • Green- and brown field production CAR-T hubs • Operational readiness and scale up SARAH SNYKERS, Senior Director of Operations, **Legend Biotech**
Q&A session & transition time between conference rooms			*Q&A session & transition time between conference rooms*	
12:50 **Customisable 3D Model Systems: A Modular Platform For Accelerating Therapeutic Research** • Bespoke Assay Design for Speed and Cost Efficiency • Systematic Screening Across Model Complexity • Biologically Relevant Models for All Modalities • Diverse Disease Areas and Cell Sources Concept Life Sciences DARRYL TURNER, Principal Scientist, **Concept Life Sciences**		*Attendees are welcome to join co-located sessions*	***Innovation & Collaboration Programme (12:50-13:00)*** **Preparing Cell Therapies For Clinics** Preparing cell therapies for the clinic is especially challenging for small biotech because CMC, GMP, and clinical startup are capital intensive. This talk shows a practical, capital-light route to first-in-human: choose an off-the-shelf allogeneic design, run PoP with research-grade material before paying for GMP, execute the trial as an IST with an academic center, outsource GMP, and early regulatory alignment (PIND/IND) to lock CMC, tox, and FIH design. SANJEEV LUTHER, President & Chief Executive Officer, **Ernexa Therapeutics**	**Securing Success By Engaging A CDMO Early** Partnering early with a CDMO is key to turning cell and gene therapy ambitions into reality. From process design to GMP manufacturing, early collaboration streamlines development, secures scalability, and minimises risks, accelerating time to market while ensuring quality, compliance, and lasting success. CELLforCURE by SEQENS LAURENT PICARD, Chief Commercial Officer, **Cell For Cure**

Day Two | 12 November 2025

CELL CULTURE & BIOPROCESSING		ADVANCED THERAPY DEVELOPMENT		CELL & GENE THERAPY MANUFACTURING
TRACK 1: GENERATION & VALIDATION OF PRE-CLINICAL MODELS & STEM CELLS CONFERENCE ROOM 1: MORANGIS	TRACK 2: DOWNSTREAM BIOPROCESSING CONFERENCE ROOM 2: BOURGOGNE	TRACK 3: CELL THERAPY DISCOVERY & DEVELOPMENT CONFERENCE ROOM 3: COGNAC	TRACK 4: CLINICAL DEVELOPMENT & CLINICAL TRIALS FOR CELL & GENE THERAPIES CONFERENCE ROOM 4: MUSCADET	TRACK 5: STRATEGIES FOR CELL THERAPY MANUFACTURING CONFERENCE ROOM 5: ALSACE

13:15 - 14:15 **LUNCH BREAK & REFRESHMENTS**

1-2-1 Meetings x3 | Poster Displays

Panel Discussion: **13:30 - 14:00 'Women in Life Sciences' Panel Discussion on the 'Visionary Voices' Stage - Conference Room 1: Morangis**

- Breaking barriers & shaping the future
- Building inclusive working environments
- Fostering the next generation

Moderator: ERIN HARRIS, Chief Editor, **Cell & Gene**

Panellists: VASILIKI KALODIMOU, Professor, **European University-Cyprus – Frankfurt Branch**
TAISIIA MUKII, Founding Ambassador, **Women In STEM Network**
RUTH FARAM, Co-Founder & Chief Scientific Officer, **SymphoRNA**

Afternoon Track Chair: LEILA ABBAS, Preclinical Lead, **Rinri Therapeutics**	**Afternoon Track Chair:** JULIE BEAUDET, Chemistry, Manufacturing, & Control Senior Staff Scientist, **Regeneron**	**Afternoon Track Chair:** TERRI GASKELL, Chief Technology Officer, **Rinri Therapeutics**	**Afternoon Track Chair:** PANTELI THEOCHAROUS, Chairman of the Board of Directors, TMOIF & Chief Executive Officer, **VectorGen**	**Afternoon Track Chair:** SABINA LANCASTER, Technical Programme Head, **Legend Bio**
INTERACTIVE ***Panel Discussion:*** **Overcoming The Challenges Of Moving From In Vivo, In Vitro To 3D Cell Models** • Modelling approaches • Modelling complex organ tissues • Qualification & validation **Moderator :** ALINE MILLER, Professor, **University of Manchester** **Panellists:** MARYNA PANAMAROVA, 3D Cellular Modelling Specialist, Cellular Operations, **Wellcome Sanger Institute** GIACOMO DOMENICI, Research Scientist, **iBET** JULIEN FLEURENCE, Discovery Safety Specialist, **AstraZeneca**	**Breaking Bottlenecks In Viral Vector Purification** Alternative purification strategies such as the use of novel adsorbents are increasingly recognised as enabling technologies that boost yield, improve vector quality, and shorten process time. This presentation will highlight the application of these strategies in the downstream processing of enveloped viruses, with a focus on gene and oncolytic therapies, including chimeric viruses platforms. CRISTINA PEIXOTO, Head Of Downstream Process Development Lab & Coordinator Of Bioproduction Unit, **iBET**	**Cell Sciences Toolbox To Support The Production, Characterisation And Selection Of Multispecific Antibodies** • Ichnos Glenmark Innovation (IGI) BEAT platform enables the generation of multispecific immune cell engagers for the treatment of cancer • Efficient protein expression and cell line engineering tools were implemented to support the production and characterisation of these multispecific immune cell engagers • The toolbox includes automated transient transfection, transposase-based pool platform and CRISPR-Cas9 Knock-Out cell line generation SARA RAMOS, Senior Investigator-Cell Sciences, **IG Innovate**	**ASPIRO: An Autologous Phase 1/2a Dopamine Neuron Restoration Trial For Parkinsons Disease** • Presentation of six-month FIH trial data showing that precision intracranial delivery of autologous iPSC-derived dopamine neuron precursor cell therapy is safe and well tolerated • Further, both patient-reported and clinician-reported outcomes demonstrate early signs of efficacy THORSTEN GORBA, Vice President Process & Analytical Development, **Aspen Neuroscience**	**External Sourcing Or In-House Manufacturing Of Gene Editing Reagents To Support The Growing Cell And Gene Therapy Business** • Gene editing – applications and reagents • Quality requirements for gene editing reagents • The manufacture of pDNA, mRNA and gRNA • The make-or-buy question - deciding to manufacture in-house or source externally, understanding the success factors, risks and mitigations ULRICH RÜMENAPP, Senior Biotech Program Lead, **Bayer**

14:15

Q&A session & transition time between conference rooms

Day Two | 12 November 2025

CELL CULTURE & BIOPROCESSING

TRACK 1: GENERATION & VALIDATION OF PRE-CLINICAL MODELS & STEM CELLS

CONFERENCE ROOM 1: MORANGIS

Development Of Human Cell Models To Study The Deregulation Of The Cell Microenvironment

As the disease and tumour microenvironment (TME) critically influences therapy response, our work focuses on developing and applying human 3D TME cell models using co-culture approaches. These models recapitulate cell–cell crosstalk and innate immune interactions, having applications in gene therapy and neuroinflammation studies in the central nervous system (CNS) as well as breast and brain tumours, including evaluation of therapeutic antibodies.

GIACOMO DOMENICI, Research Scientist,
iBET

TRACK 2: DOWNSTREAM BIOPROCESSING

CONFERENCE ROOM 2: BOURGOGNE

Template-Assisted Biocrystallisation In Vitro & In Vivo For Future Manufacturing Of Biopharmaceuticals

We developed templating strategies—rigid, hydrogel, gas, and cell-based—to accelerate protein crystallisation, overcoming slow kinetics. Inspired by nature, we pioneered intracellular templating to form protein crystals in living cells, offering cost-effective biomanufacturing solutions with strong industrial potential.

HUAIYU YANG, Senior Lecturer,
Loughborough University

ADVANCED THERAPY DEVELOPMENT

TRACK 3: CELL THERAPY DISCOVERY & DEVELOPMENT

CONFERENCE ROOM 3: COGNAC

Innovation & Collaboration Programme:

Presentation 1: HepatiCan, A Combined Cell Therapy And Medical Device To Rescue Patients With Severe, Acute Liver Failure

I will discuss the unmet clinical need for patients with liver failure and introduce HepatiCan a cryopreservable cell therapy and medical device, sharing preclinical trial data and device design, as well as discuss the current challenges for ATMPs in the context of a small Biotech SME.

CLARE SELDEN, Founder,
HepatiCan Ltd

Presentation 2:

Jetbio: Reactive Jet Impingement Bioprinting For 3D Tissue Cultures

Jetbio is commercialising a new patented bioprinting technique: reactive jet impingement. The printing technique offers the ability to print very high cell densities, and the ability to print onto delicate or complex substrates. This allows in vitro models incorporating tissue and biomimetic substrates to create more representative in vitro models.

KENNY DALGARNO, Professor,
Newcastle University

TRACK 4: CLINICAL DEVELOPMENT & CLINICAL TRIALS FOR CELL & GENE THERAPIES

CONFERENCE ROOM 4: MUSCADET

Cilta-Cel: Changing The Treatment Paradigm In Multiple Myeloma

Overview of the Cilta-Cel clinical development programme, including emerging long term follow up data. Opportunities to move into frontline treatment for multiple myeloma.

NITIN PATEL, Vice President Of Late-Stage Clinical Development,
Legend Biotech

CELL & GENE THERAPY MANUFACTURING

TRACK 5: STRATEGIES FOR CELL THERAPY MANUFACTURING

CONFERENCE ROOM 5: ALSACE

Innovation In Action: The Adoption Of ATMPs In The NHS

- How does NHS England commission ATMPs?
- Some facts and figures
- What is our strategic approach to commissioning ATMPs?
- What has been achieved to date?

SARAH MCALEER, Pharmacy Lead - Innovative Treatments,
NHS

KIRAN MOYO, National Senior Manager - Innovative Treatments,
NHS

14:40

Q&A session & transition time between conference rooms

Day Two | 12 November 2025

CELL CULTURE & BIOPROCESSING

TRACK 1: GENERATION & VALIDATION OF PRE-CLINICAL MODELS & STEM CELLS

CONFERENCE ROOM 1: MORANGIS

Track And Trace Your Cell Conditions Via Real-Time Cellular Metabolism Monitoring

Cell energy utilisation, such as glucose consumption, reflects key cellular states like stem cell differentiation, immune activation, and tumour growth.
In this talk, we introduce the Live Cell Metabolic Analyzer (LiCellMo), powered by PHCbi's proprietary in-line sensor technology, and will showcase how it enables real-time, long-term glucose and lactate monitoring for precise cell condition tracking and culture optimisation.

15:05

PHC Europe
A Member of PHC Group.

ASHLEY SHIH, Application Specialist of Cell and Gene Therapy Department, **PHC Europe**

TRACK 2: DOWNSTREAM BIOPROCESSING

CONFERENCE ROOM 2: BOURGOGNE

Innovation & Collaboration Programme:

Presentation 1: Putting Our Brains In Drug Discovery

Brain organoids: a biomedical revolution mimicking brain development and function and is scalable for high-throughput patient neural network screening. This presentation covers a:head bio's brain organoid-based drug discovery efforts.

JOSHUA BAGLEY, Chief Scientific Officer, **a:head Bio**

Presentation 2:
AI-powered Targeted Lipid Nanoparticles With Unique Combinations Of Peptides For Specific Delivery Of Genetic Medicines

Nanograb uses AI to design targeted lipid nanoparticles for delivering advanced therapies such as mRNA or gene editing payloads to specific cells and tissues in the body. Our proprietary computational pipeline generates unique combinations of peptides which are conjugated onto the surface of LNPs for targeted delivery.

DEBESH MANDAL, Co-Founder & Chief Executive Officer, **Nanograb**

ADVANCED THERAPY DEVELOPMENT

TRACK 3: CELL THERAPY DISCOVERY & DEVELOPMENT

CONFERENCE ROOM 3: COGNAC

INTERACTIVE

Panel Discussion: **Navigating Global Regulatory Challenges In Cell & Gene Therapy**

- Diverging regulatory pathways
- Exploring ongoing initiatives for global regulatory convergence
- Lessons learned from the past 10 years of ATMPs in the stage of standardisation

Moderator:

PAULINE LESTRINGANT, Director Regulatory Science, **Voisin Consulting Life Science**

Panellists:

FRANÇOIS GIANELLI, Chief Regulatory & Quality Officer, **TreeFrog Therapeutics**

JAS UPPAL, Senior Vice President Head of Regulatory, **BlueRock Therapeutics**

TRACK 4: CLINICAL DEVELOPMENT & CLINICAL TRIALS FOR CELL & GENE THERAPIES

CONFERENCE ROOM 4: MUSCADET

Enhancing The Efficacy Of Solid Tumour Chemotherapy - Modulating Tumour Micro-Environment

AeirBio's lead compound CMX103 temporarily 'normalises" tumour microenvironment, restoring tumour-cell-membrane ceramide levels and enhancing ENT1 activity. This approach increases response rates to gemcitabine from 38% in control group to 93% in the active treatment arm in a clinical study in Sarcoma patients.

ROELOF RONGEN, Co-Founder & Board Director, **AeirBio**

CELL & GENE THERAPY MANUFACTURING

TRACK 5: STRATEGIES FOR CELL THERAPY MANUFACTURING

CONFERENCE ROOM 5: ALSACE

Flask-Based Automation Platform To Unlock Scalable Manufacturing Of Regenerative Medicine

Mytos is a vertically integrated automated cell culture CDMO leveraging proprietary flask-based automation and closed-system processes. We deliver scalable, consistent, and cost-effective manufacturing solutions that help partners accelerate the development and production of advanced cell therapies.

Mytos

XIAN WENG, Director of Product Solutions, **Mytos**

Q&A session & transition time between conference rooms

Day Two | 12 November 2025

	CELL CULTURE & BIOPROCESSING		ADVANCED THERAPY DEVELOPMENT		CELL & GENE THERAPY MANUFACTURING
	TRACK 1: GENERATION & VALIDATION OF PRE-CLINICAL MODELS & STEM CELLS CONFERENCE ROOM 1: MORANGIS	TRACK 2: DOWNSTREAM BIOPROCESSING CONFERENCE ROOM 2: BOURGOGNE	TRACK 3: CELL THERAPY DISCOVERY & DEVELOPMENT CONFERENCE ROOM 3: COGNAC	TRACK 4: CLINICAL DEVELOPMENT & CLINICAL TRIALS FOR CELL & GENE THERAPIES CONFERENCE ROOM 4: MUSCADET	TRACK 5: STRATEGIES FOR CELL THERAPY MANUFACTURING CONFERENCE ROOM 5: ALSACE
15:30	**Moving Towards Animal Free 3D Cell Culture And Organoid Growth For Drug Discovery** • Advancing Animal-Free 3D Cell Culture: Development of biomimetic scaffolds and hydrogel systems that replace animal-derived matrices, enabling more physiologically relevant and ethically responsible research • Improving Translational Relevance: Use of engineered 3D environments that better replicate native human tissue architecture, enhancing predictive accuracy for drug discovery and reducing reliance on in vivo models • Enabling Scalable & Sustainable Drug Development: Innovations in synthetic, reproducible, and tuneable growth platforms designed to support high-throughput screening and accelerate the pathway to clinical translation ALINE MILLER, Professor, **University of Manchester**	**Purification Platform Development For The Purification For rAAV Vectors** • Challenges currently facing rAAV purification • Development of platform approaches to chromatography process development JESSICA WHELAN, Lecturer, **University College Dublin**	**From iPS To Blood Cells Using Platform Technology** Plasticell invented a unique screening platform CombiCult, which allows to test up to thousands of cell culture media compositions in a single experiment. It's use supports the development of advanced cell therapies through differentiation or expansion of stem cells. Getting blood cells from iPSCs presents novel ways to treat blood loss or cancers. TATYANA PONOMARYOV, Principal Scientist, **Plasticell**	**A Combined ATMP & Medical Device For Patients With Liver Failure. An Academic's Path From Basic Science To Translational Medicine** I will discuss the unmet clinical need for patients with liver failure and introduce HepatiCan a cryopreservable cell therapy and medical device, sharing preclinical trial data and device design, as well as discuss the current challenges for ATMPs. CLARE SELDEN, Professor of Experimental Hepatology, **University College London**	**Robotics, Computer Vision & Machine Learning: The Muscles, Eyes & Smarts Of Automated CGT Manufacturing** This presentation highlights our end-to-end automation platform, enabling reproducible manufacturing of autologous iPSC-derived cell therapies utilising robotics and AI/ML image analysis software. The impact of process closure and automation on scalability and reduction of labor & training, COGS and cleanroom footprint will be explained. THORSTEN GORBA, Vice President Process & Analytical Development, **Aspen Neuroscience**
15:55 - 16:10	AFTERNOON COFFEE & REFRESHMENTS				

Day Two | 12 November 2025

	CELL CULTURE & BIOPROCESSING		ADVANCED THERAPY DEVELOPMENT		CELL & GENE THERAPY MANUFACTURING
	TRACK 1: GENERATION & VALIDATION OF PRE-CLINICAL MODELS & STEM CELLS CONFERENCE ROOM 1: MORANGIS	TRACK 2: DOWNSTREAM BIOPROCESSING & INNOVATION & COLLABORATION PROGRAMME CONFERENCE ROOM 2: BOURGOGNE	TRACK 3: CELL THERAPY DISCOVERY & DEVELOPMENT CONFERENCE ROOM 3: COGNAC	TRACK 4: CLINICAL DEVELOPMENT & CLINICAL TRIALS FOR CELL & GENE THERAPIES CONFERENCE ROOM 4: MUSCADET	TRACK 5: STRATEGIES FOR CELL THERAPY MANUFACTURING CONFERENCE ROOM 5: ALSACE
16:10	***Focused Stem Cells Session*** **2 Years Results Of A Case Series Of Lipogems Microfragmented Fat, (MSC's), For Cartilage & Joints Arthritis** • Sustained Clinical Improvement: Patients with early to moderate knee osteoarthritis (OA) exhibited significant and lasting improvements in pain, function, and joint mobility up to two years post-treatment. Notably, the Lysholm and WOMAC scores remained significantly higher than baseline, indicating durable benefits from the MFAT injections • Safety Profile: The procedure demonstrated a high safety profile, with no major complications reported during the two-year follow-up period. This suggests that MFAT injections are a viable minimally invasive option for managing knee OA • Predictive Factors for Treatment Success: While the overall outcomes were positive, certain factors such as synovitis were associated with higher treatment failure rates. This highlights the importance of patient selection and the need for further research to identify optimal candidates for MFAT therapy VASILIKI KALODIMOU, Professor, **European University-Cyprus – Frankfurt Branch**	INTERACTIVE ***Panel Discussion:*** Streamlining Bioprocessing: Automation & Integration In Downstream • Workflows • Rapid optimisation & process integration • Future trends **Moderator:** JESSICA WHELAN, Lecturer, **University College Dublin** **Panellists:** CRISTINA PEIXOTO, Head Of Downstream Process Development Lab, **iBET** HUAIYU YANG, Senior Lecturer, **Loughborough University**	INTERACTIVE ***Panel Discussion:*** Bridging The Gap Between R&D And Manufacturing For Digital & Automation Solutions • Moving from discovery through the pipeline • Challenges in technology implementation • Benefits to scalability of manufacturing **Moderator:** TIFFANY RAU, Professor Biochemistry & Cell Biology, **University College Cork** **Panellists:** DARIA MARSH, Head of Bioprocessing, **Cell & Gene Catapult** NORMAN TRAPP, Principal Scientist, **Sartorius**	**Leveraging Agency Interactions To Fast Track ATMP Development In Rare Diseases** This talk explores how proactive, strategic interactions with regulatory authorities and payers —beyond standard scientific advice—can transform ATMP development in rare diseases. By leveraging regulatory mechanisms, and timing investments to anticipate hurdles, sponsors can accelerate progress and de-risk development. Benchmarks and pitfalls illustrate actionable lessons for successful regulatory approval and market launch. PAULINE LESTRINGANT, Director Regulatory Science, **Voisin Consulting Life Sciences**	**Advances In Manufacturing Of iPSC Derived NK Cells For Immunotherapy** iPSC-derived immunotherapies provide a scalable, lower cost alternative to allogeneic donor-derived products. Plasticell employed its combinatorial screening technology, CombiCult®, to develop robust, feeder-free, serum-free, GMP-compliant protocols for production of Natural Killer (NK) cells from human iPSCs (iNK cells). Agitated culture manufacturing generated functionally mature iNK cells with increased yield, efficiency and purity. MARINA TARUNINA, Research Director, **Plasticell**

Q&A session & transition time between conference rooms

Book Now

LinkedIn

@NextGenBiomedOG

Day Two | 12 November 2025

CELL CULTURE & BIOPROCESSING

TRACK 1: GENERATION & VALIDATION OF PRE-CLINICAL MODELS & STEM CELLS
CONFERENCE ROOM 1: MORANGIS

16:35

Focused Stem Cells Session

AI For Rejuvenation & Replacement Therapies

- Autologous iPSC-derived hematopoietic stem cells for immune and blood system rejuvenation
- AI-driven transcription factor engineering in collaboration with OpenAI
- Translating rejuvenation biology into next-generation cell therapies

JOE BETTS-LACROIX, Chief Executive Officer,
Retro Biosciences

TRACK 2: DOWNSTREAM BIOPROCESSING & INNOVATION & COLLABORATION PROGRAMME
CONFERENCE ROOM 2: BOURGOGNE

INTERACTIVE

Panel Discussion:
Challenges Of Navigating Development & How To Get To The Clinic

- Funding: how to start strategising to secure funding
- Regulatory guidelines
- Manufacturing priorities

Moderator:

BO WIINBERG, Chief Development Officer, **Novo Nordisk Foundation Cellerator**

Panellists:

SANJEEV LUTHER, President & Chief Executive Officer, **Ernexa Therapeutics**

LUCY WILLIAMS, Partner, European & UK Patent Attorney, **J A Kemp**

ADVANCED THERAPY DEVELOPMENT

TRACK 3: CELL THERAPY DISCOVERY & DEVELOPMENT
CONFERENCE ROOM 3: COGNAC

INTERACTIVE

Panel Discussion: **Assessing Current & Future Opportunities In Bringing Cell Therapies To New Spaces**

- Current landscape
- Identifying unmet needs & new targets

Moderator:

GRAY KUEBERUWA, Chief Executive Officer, **Immunokey**

Panellists:

TIFFANY RAU, Professor Biochemistry & Cell Biology, **University College Cork**

PANTELI THEOCHAROUS, Chairman of the Board of Directors, TMOIF & Chief Executive Officer, **VectorGen**

TERRI GASKELL, Chief Technology Officer, **Rinri Therapeutics**

TRACK 4: CLINICAL DEVELOPMENT & CLINICAL TRIALS FOR CELL & GENE THERAPIES
CONFERENCE ROOM 4: MUSCADET

Phase 3 Trials For A Cell Therapy For Parkinsons Disease

- Design and objectives of the first Phase 3 trial of a stem cell–derived dopaminergic therapy in Parkinson's disease
- Insights from Phase 1 and the path toward pivotal evidence in motor symptom improvement
- Clinical, surgical, and regulatory considerations in advancing cell therapies to approval

JAS UPPAL, Senior Vice President Head of Regulatory,
BlueRock Therapeutics

CELL & GENE THERAPY MANUFACTURING

TRACK 5: STRATEGIES FOR CELL THERAPY MANUFACTURING
CONFERENCE ROOM 5: ALSACE

Pluripotent Stem Cells Manufacturing For Making And Repairing Human Hearts

Human pluripotent stem cell (hPSC) technology is a versatile approach. Present matrix-free, advanced hPSCs bioprocessing and upscaling in fully controlled stirred tank bioreactors in suspension culture and their directed differentiation into specific lineages, particularly hPSC-derived cardiomyocytes. Strategies for their clinical translation will be discussed, in particular cardiac aggregate transplantation into a non-human primate model of myocardial infarction. Heart forming organoids and blood-generating HFOs will be introduced. These complex, highly structured multi-tissue models reflect aspects of early human development in a dish, including the co-development of the heart anlagen, vasculature, foregut and haematopoiesis.

ROBERT ZWEIGERDT, Professor & Principal Investigator,
Hannover Medical School

17:00 **END OF CONFERENCE**

VENUE INFORMATION

Experience London

Just minutes from three of London's main tube lines (Piccadilly, District and Hammersmith & City) and located in the heart of Hammersmith; Novotel London West is ideally located for trips to Westfield London, Harrods & Kensington High Street. Also conveniently located to Heathrow Airport with excellent road and rail links to the rest of the UK.

This large and modern hotel offers on-site parking (chargeable), fitness suite and complimentary Wi-Fi throughout.

DIRECTIONS BY AIR

- London Heathrow Airport - Novotel London West is accessible from Heathrow via the Underground on the Piccadilly Line - fares cost around £5 into Central London. A taxi from the airport will take approximately 20 minutes and will cost around £30 - £40.
- London Gatwick Airport - The Gatwick Express runs every 15 mins - take it to Victoria station, and then get the District line to Hammersmith (about 15 mins). A taxi from the airport will take around 60 mins and cost between £65 - £80.

BY UNDERGROUND & BUS

- Hammersmith Underground Station is adjacent to the hotel (3 minutes walk) with access to the Piccadilly, District and Hammersmith & City Lines. When exiting Hammersmith station, turn right and walk across the bus station. Cross over the roads using the island and keep on the right-hand side of Hammersmith Road. Continuing walking for 2 mins, and the hotel is accessible via stone steps.
- For buses in central London, take route numbers 9 and 10. The main coach station (London Hammersmith) is 3 minutes walk away.

BY RAIL

- The closest National Rail train station is Kensington Olympia (20 minutes walk).

BY CAR

- Leave the A4 at the Hammersmith turning and proceed along Hammersmith Bridge Road to the large roundabout underneath the flyover. Take the fifth exit off the roundabout. Then turn left into Shortlands - the main hotel entrance and parking will be on your left-hand side.

NOVOTEL
HOTELS, SUITES & RESORTS

1 Shortlands, Hammersmith,
W6 8DR London

Explore the Hotel